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CHAPTER 1: INTRODUCTION 
1.1 DCIS (Ductal Carcinoma In situ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Mortality from breast cancer has declined for the past two decades, and this 
decline (Siegel, Naishadham et al. 2012) was thought due to both introduction of 
screening programs in the 1980s, resulting in earlier diagnosis and intervention (Kopans 
2011, Puliti and Zappa 2012), and the development and optimization of chemotherapy 
(Early Breast Cancer Trialists' Collaborative, Peto et al. 2012). Meta-analysis of 11 
randomized clinical trials with 13 years follow-up estimated reduction of 20% of cancer 
in women invited for screening (Independent 2012).   
DCIS (Ductal Carcinoma in situ) accounts for 15%-25% of newly diagnosed 
breast cancer cases in the United States (Polyak 2010).  DCIS, by definition, is a non-
invasive cancer.  It is characterized by the accumulation of abnormal cells in the 
mammary duct without invasion into the basement membrane and into the stroma 
(Burstein, Polyak et al. 2004). Unlike the dramatic improvement in the detection of 
DCIS, the molecular mechanisms that govern the progression to invasive phenotype are 
shrouded in mystery. Until 1980, DCIS represented less than 1% of breast cancer (Van 
Cleef, Altintas et al. 2014).  Apparent incidence has increased, in part, due to the 
increasing use of mammography screens and improved imaging technologies (Kuerer, 
Albarracin et al. 2009). This means that more DCIS lesions are detected earlier and 
more frequently due to improvements in imaging technology (i.e., mammograms). 
Overdiagnosis is a direct result of mammography and is manifested by the 
dramatic increase in DCIS (Gotzsche and Nielsen 2011, Gotzsche, Jorgensen et al. 
2012).  Overdiagnosis refers to a detection of subclinical disease that, if left untreated, 
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would not cause symptoms or death. The National Institutes of Health Office of Medical 
Application Research commissioned a review on the incidence, treatment and 
outcomes of DCIS (Virnig, Tuttle et al. 2010).  The results led to the conclusion that the 
incidence of DCIS has risen from 1.87 per 100,000 in 1973 to 3.25 in 100,000 in 2004, 
with the increase mostly accounted for by the introduction of screening mammography 
(Virnig, Tuttle et al. 2010).  Recently, Welch et al. used 1975-2012 data from the SEER 
(Surveillance, Epidemiology and End Results) database to calculate the tumor-size 
distribution and size specific incidence of breast cancer among women 40 years and 
older (Welch, Prorok et al. 2016). They concluded that after the introduction of 
screening, the proportion of detected breast tumors that were small (invasive tumors 
measuring <2 cm or in situ tumors) increased from 36% to 68%. The proportion of 
detected tumors that were large (invasive tumors measuring ≥ 2 cm) was decreased 
from 64% to 32%. The authors concluded that although the rate of detection of large 
tumors fell after the introduction of screening, this distribution was primarily the result of 
additional detection of small tumors. They add that women are more likely to have 
breast cancer overdiagnosed than have earlier detection of a tumor that was destined to 
grow in size. 
Some DCIS, if left untreated, will rapidly progress to invasive cancer and/or recur 
following treatment whereas others will remain indolent (not grow or progress to an 
invasive disease that may require therapeutic intervention). Thus, once DCIS is 
detected, treatment is frequently offered to women even though the majority present 
with an indolent form of DCIS (Sanger, Engels et al. 2014), resulting in overtreatment. 
Overdiagnosis leads to overtreatment that may not benefit the patient and can 
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potentially harm her because of overdiagnosed disease. The “harm” is the cost to a 
woman’s mental (anxiety) and physical well-being (i.e., side effects from unnecessary 
treatment).  A consequence of overdiagnosis is that in some cases, women have their 
cancer treated by surgery, radiation therapy or medication, but neither the woman nor 
the physician can know whether this cancer would be the one that could possibly lead to 
death or one that would have remained undetected for the rest of the woman’s life 
(Independent 2012).  An indolent DCIS, if left alone, is less likely to threaten the 
patient’s health within her lifetime and therefore does not require treatment (Kaur, Mao 
et al. 2013). The current recommended treatment for DCIS is wide excision 
lumpectomy, with or without radiation, mastectomy or hormone therapy after surgery 
(http://www.breastcancer.org).  Out of 496,488 women diagnosed with DCIS, 33.4% 
had a single mastectomy and 7.0% had a contralateral prophylactic mastectomy 
(removal of the opposite healthy breast) (Wong, Freedman et al. 2016). 
The issue of overdiagnosis and overtreatment has led to the launching of clinical 
trials that address the management of low risk DCIS.  For example, LORD 
(Management of Low-risk DCIS), sponsored by the European Organization for 
Research and Treatment of cancer, is a randomized, international, multicenter phase III 
trial that aims to determine whether screen-detected low-grade DCIS can safely be 
managed by an active surveillance strategy or conventional treatment (radiation) over a 
10 year period.  The primary outcome is an ipsilateral recurrence (defined by location on 
the same side as primary lesion) and survival without invasive breast cancer 
(https://clinicaltrials.gov/ct2/show/NCT02492607?term=DCIS). This new trial is just 
beginning to accrue patients and so results are not available. Another recent project, 
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named WISDOM (Women Informed to Screen Depending on Measures Risk) aims to 
investigate whether a an individualized (tailored to the individual patient; based on 
family history) approach to breast cancer screening is as safe and effective as annual 
mammograms (J. Clin Oncol 34, 2016 suppl; abstr e 13035). Therefore, it is important 
to distinguish between which lesions will progress to invasive breast cancer, and to 
illuminate the pathways that drive the progression to IDC (invasive ductal cancer).   
Additional clinical trials address the efficacy of current treatment options, such as the 
sole employment of wide-excision without radiation therapy for treatment of small DCIS 
of grade 1-2 (https://clinicaltrials.gov/ct2/show/NCT00165256). 
DCIS is heterogeneous, expressing a variety of markers such ER (Estrogen 
Receptor), PR (Progesterone Receptor), HER2/ERBB2 (Human Epidermal Growth 
Factor Receptor), etc. To address this heterogeneity, multiple clinical trials have been 
designed to assess the treatment of DCIS, tailored to the expression of these markers.  
For example, clinical trials evaluating the treatment of HER2/EGFR expressing DCIS (of 
high grade) with lapatinib were designed to test the inclusion of lapatinib treatment as 
an interval between biopsy diagnosis and surgery.  This study was terminated due to 
low accrual (https://clinicaltrials.gov/ct2/show/NCT00555152?term=DCIS&rank=21). 
Meta-analyses have also been performed on multiple studies focusing on DCIS.  
Analyses were performed by the Cochrane Breast Cancer Group in 2013 on four 
randomized controlled trials totaling of 3925 women. They compared treatment with 
breast conserving surgery alone vs. breast conserving surgery with the addition of 
radiation therapy. The results suggested that the addition of radiation therapy reduced 
the risk of recurrence of either DCIS or breast cancer in the treated breast by 51%, with 
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no long-term toxicity from radiotherapy (Goodwin, Parker et al. 2013).  Another review, 
published in 2012 by the same group, examined whether women taking tamoxifen lived 
longer compared to those who did not take hormone therapy after local excision. The 
findings were based on two large studies with 3375 participants.  The review states that 
even though administration of tamoxifen after local excision of DCIS reduced the risk of 
DCIS recurrence, it did not reduce the risk of overall mortality (Staley, McCallum et al. 
2012).  The results of other clinical trials suggest that treatment of DCIS with adjuvant 
tamoxifen may be beneficial to DCIS patients. A NSABP (National Surgical Adjuvant 
Breast and Bowel Project) B24 study was performed to retrospectively evaluate the 
benefits of adjuvant tamoxifen in patients with DCIS after lumpectomy and radiation 
(Allred, Anderson et al. 2012). The results of the study suggest that treatment of DCIS 
with tamoxifen after lumpectomy and radiation conferred benefit to patients with ER+ 
DCIS.  Patients with ER-positive DCIS treated with tamoxifen (vs placebo) showed 
significant decrease in subsequent breast cancer at 10 years. No significant benefit was 
observed in ER- DCIS. One thousand seven hundred and ninety-nine patients were 
recruited.  The absolute risk of ipsilateral or contralateral recurrence was reduced from 
19 per 1000 women to 6 per 1000 women. These data suggest that adding tamoxifen 
post-lumpectomy/radiation may benefit patients. 
Previous expression profiling studies have demonstrated that very few genes are 
differentially expressed between DCIS and invasive breast cancer of similar grade (Ma, 
Salunga et al. 2003, Porter, Lahti-Domenici et al. 2003, Chin, de Solorzano et al. 2004, 
Sgroi 2010). A few include COX2, Ki67 and pRB (Polyak 2010). Our previous RNAseq 
studies also found down-regulation of DST, HSRA1 and TGFBI in the progression to 
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DCIS (Kaur, Mao et al. 2012), which is in agreement with other studies (Calaf, Echiburu-
Chau et al. 2008, Lee, Stewart et al. 2012, Wang, Eckert et al. 2012).  Molecular 
screening approaches have been developed, and they are useful in making informed 
decisions about post-surgery adjuvant treatments or recurrence (Rudloff, Jacks et al. 
2010). A subset of markers from the 21 gene Oncotype DX® test can predict the 
likelihood of progression (Solin, Gray et al. 2013). A recent pooled analysis of four 
prospective studies regarding the application of Oncotype DX to ER+ HER2- patients 
has been performed. The conclusion was that employment of this test led to the 
decrease in chemotherapy recommendation rate by 11% (from 55% to 44%).  The 
highest change in chemotherapy recommendation rates were in patients who would 
have been originally recommended for chemotherapy for grade 2 tumors (Albanell, 
Svedman et al. 2016).  The Oncotype DX DCIS Score –short form estimates the risk of 
ipsilateral breast recurrences in patients with DCIS treated with breast conserving 
surgery without adjuvant radiation therapy.  Recent studies were also designed to 
evaluate the cost effectiveness of using the Oncotype DX DCIS score in the treatment 
of women diagnosed with DCIS. The authors concluded that even though usage of the 
DCIS score lowered the proportion of women undergoing radiation therapy, 
incorporation of the DCIS score was not cost effective (Raldow, Sher et al. 2016). The 
authors emphasize the importance of engaging patients in the complex and 
controversial decision making process. 
 In the traditional breast cancer progression model, invasive breast cancers were 
thought to rise through a stepwise linear progression from normal breast epithelium to 
hyperplasia to atypical hyperplasia to ductal carcinoma in situ to invasive breast cancer, 
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resulting from progressive accumulation of genetic mutations in epithelial tissue. This 
progression model has been supported by human clinical and epidemiological data and 
by molecular clonality studies addressing the relationships between in-situ and invasive 
areas of the same tumor and DCIS and local invasion (Polyak 2010).  Other models of 
breast cancer progression are proposed.  For example, the non-linear or branched 
progression models propose that DCIS would be a precursor to IDC, but different 
grades of DCIS would progress to IDCs of the same grade (Wellings and Jensen 1973).  
Another model of progression proposes that DCIS and IDC could develop from 
the same progenitor cell and progress independently (Sontag and Axelrod 2005). Some 
evidence suggests that DCIS may even regress. Histological studies performed on high 
grade DCIS show evidence of regression. This is possibly due to factors such as 
fibrosis, chronic inflammation, and the presence of periductal T cells that elicit a 
targeted immune response to certain lesions (Wasserman and Parra-Herran 2015).  
The authors also suggest that an immune response is likely to eradicate those tumors 
with high immunogenicity, thus selecting for less immunogenic clones. 
Analysis of clinical specimens has revealed several features of DCIS that are 
associated with progression to invasive cancer (Knudsen, Ertel et al. 2012, Lee, Stewart 
et al. 2012). Gene profiling studies from several groups comparing DCIS to invasive 
breast cancer have shown that gene expression programs associated with EMT 
(epithelial to mesenchymal transition) are associated with invasive breast cancer 
(Knudsen, Ertel et al. 2012, Lee, Stewart et al. 2012, Witkiewicz, Cox et al. 2014).  One 
conclusion from these results is that DCIS undergoing EMT would have the propensity 
to progress in invasive disease.  Cell-cell junctions and basal attachment to the 
  8 
 
membrane are lost during the process of EMT and are associated with invasive disease 
(Witkiewicz, Cox et al. 2014).  
Interestingly, other reports also indicate that epigenetic alterations and tumor 
environment play a role in DCIS progression. Analysis of bulk and micro-dissected 
tissues has suggested that genes differentially expressed between DCIS and IDC are 
enriched for changes in processes related to the tumor microenvironment (Lee, Stewart 
et al. 2012, Vargas, McCart Reed et al. 2012). Additional reports have provided 
evidence that epigenetic changes (Widschwendter and Jones 2002, Fleischer, Frigessi 
et al. 2014) contribute to DCIS progression, and may be mediated by myoepithelial cells 
(Hu, Yao et al. 2008). 
It is important to mention that breast cancer has been characterized into 5 
different subtypes, with distinct molecular features.   Sorlie et al reported a distinctive 
“molecular portrait” of breast cancer using 456 cDNA clones (Perou, Sorlie et al. 2000, 
Sorlie, Perou et al. 2001).  The tumors were classified into five intrinsic subtypes with 
distinct clinical outcomes, i.e., luminal A, luminal B, HER2-overexpression, basal-like 
and normal like tumors (Sorlie, Tibshirani et al. 2003). These subtypes have been 
validated by IHC (immunohistochemistry) with some exceptions (Parker, Mullins et al. 
2009).  Luminal A is characterized as ER (Estrogen Receptor)/PR (Progesterone 
Receptor) positive. The luminal B subtype is characterized as ER or PR positive, and 
HER2 (Human Epidermal Growth factor receptor 2) positive. HER2 overexpressing 
types are characterized by HER2 enrichment, while being ER/PR negative. Basal like 
breast cancer is characterized as triple negative. These subtypes have been associated 
with different prognoses. Patients with luminal A tumors have the best prognosis and 
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patients with basal like breast cancer have the worst prognosis. Patients can be 
separated for treatment options based on their subtypes (Hon, Singh et al. 2016). This 
classification relates to the types of patient-derived breast cancer cell lines used in this 
dissertation. For example, MCF-7 and T47-D are invasive breast cancer cell lines of 
luminal A subtype; they express both ER and PR without HER2 amplification (Neve, 
Chin et al. 2006, Prat, Parker et al. 2010).  MDA-MB-231, BT-549 and Hs578t are triple 
negative basal breast cancer cell lines (Neve, Chin et al. 2006, Prat, Parker et al. 2010). 
Heterogeneity is also observed in invasive and pre-invasive DCIS with similar 
variation in clinicopathological features such as histological grade, ER/PR expression, 
HER2/ERBB2 status (Livasy, Perou et al. 2007, Clark, Warwick et al. 2011). This is 
particularly important, since reports have proposed that molecular features (gene 
signatures) associated with disease progression are unique to intrinsic subtypes 
(Lesurf, Aure et al. 2016).  For example, invasive gene signatures for the Luminal A 
subtype was enriched for immune and cell cycle processes. Luminal B subtypes 
contained invasive signature enriched for immune-related responses, cell metabolism 
and cell cycle.  The invasive signature for the HER2 expressing subtype was enriched 
for cell adhesion, ECM-receptor interaction and cell motility (Lesurf, Aure et al. 2016). 
These results of this study point to the hypothesis that each specific subtype undergoes 
a distinct evolutionary course of disease progression from pre-invasive to invasive 
stage. 
Deregulation of tumor suppressors has been documented in the progression of 
DCIS to invasive breast cancer.  Rb (retinoblastoma) is a key negative regulator of 
proliferation and connects multiple signaling pathways to cell cycle machinery (Cobrinik 
  10 
 
2005, Knudsen and Knudsen 2008).  Studies have indicated that the disruption of the 
Rb tumor suppressor pathway is significantly associated with recurrence and disease 
progression of DCIS in multiple independent cohorts.  The analysis of the cohorts 
included direct staining and use of surrogate markers such as p16ink4a and Ki67 
(Gauthier, Berman et al. 2007, Ertel, Dean et al. 2010, Kerlikowske, Molinaro et al. 
2010, Knudsen, Pajak et al. 2012). However, Rb disruption alone may not be sufficient 
and might require overexpression of an oncogene, such as ErbB2.  Studies indicate that 
ErbB2 over expression is frequently found in DCIS; one study documented ErbB2 
overexpression in more than half of the DCIS cases analyzed (Allred, Clark et al. 1992, 
Hoque, Sneige et al. 2002). Studies have implicated the cooperation of loss of the Rb 
pathway and ErbB2 over-expression in specifically driving DCIS progression by 
deregulation of mammary cell proliferation, acinar morphology (Witkiewicz, Cox et al. 
2014). This is one instance in which loss of tumor suppression and over-expression of 
oncogenes together drive the progression of DCIS to invasive breast cancer. 
1.2 MCF10 Progression Series 
The MCF10 progression series has been employed for this dissertation research. 
The model of the MCF10 family of cell lines was developed by investigators at the 
Michigan Cancer Foundation, now known as Karmanos Cancer Institute.  The basis of 
the model is the human cell line of MCF10A, which was isolated from breast tissue, 
showing very mild, hyperplastic changes and extensive fibrocystic phenotype.   This 
breast tissue was from a 36-year-old woman who was in good health with no evidence 
of malignancy (Miller, Soule et al. 1993).  MCF10A is one of the series of cell lines that 
was established by the spontaneous immortalization of the original, mortal cultures. 
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These cells, though immortalized, grow in a confined monolayer with contact inhibition.  
The transformed MCF10.Neo T cell line was then derived from the MCF10A after 
transfection with mutated T24 H-ras.  When injected into immunodeficient nude mice, 
the MCF10.Neo T cells develop into a series of cell lines, including MCF10.AT1 and 
MCF10.DCIS (Miller, Soule et al. 1993, Dawson, Wolman et al. 1996). MCF10.Neo T 
cells form small flat nodules (Dawson, Wolman et al. 1996). MCF10.CA1d cell line is 
one of five tumorigenic cell lines derived from xenografts after trocar transplantation of 
organoids. The organoids were derived from transplantation of MCF10AT1K.cl2 cells 
into mice. The other cell lines are MCF10.CA1a, MCF10.CA1b and MCF10.CA1c 
(Santner, Dawson et al. 2001). MCF10.CA1d  cells have been employed in this project. 
1.3 Next Generation Sequencing and Rap1Gap 
High throughput gene expression analysis has been used to identify genes that 
may be up or down-regulated throughout the premalignant and malignant progression of 
breast cancer. Previously, NGS (next generation sequencing) was performed on RNA 
samples obtained from the Mattingly and Sloane laboratories from cells grown on rBM 
(reconstituted basement membrane). The purpose was to identify a panel of genes that 
could be involved in development of DCIS. Three different models of DCIS were used 
(MCF10.DCIS, SUM 102 and SUM 225) in comparison to MCF10A (representing non-
transformed breast epithelium). SUM 102 was derived from a surgical resection of a 
DCIS with micro-invasion and SUM 225 was derived from a chest wall recurrence in a 
patient originally diagnosed with DCIS (Ethier, Mahacek et al. 1993, Ethier 1996). Data 
analysis was performed by the Krawetz laboratory. By comparing the number of reads 
on each gene in three DCIS cell lines with that in the control MCF10A cells, the 
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expression of 157 genes was found to be significantly altered (fold change > 4) with 63 
being increased in expression in all three DCIS cell lines.  Fig. 1.1 is a Venn diagram of 
results from mRNA-Seq analysis of three models of DCIS compared to MCF-10A, which 
have been published (Kaur, Mao et al. 2012). The 63 significantly increased genes 
common to all three DCIS cell lines included Rap1Gap, a negative regulator of Rap1 
GTPase activating protein.  Genomatix analysis was used to further analyze the mRNA 
seq results to gain insights into the common frameworks in the promoter regions of the 
63 upregulated genes that were found in all three models of DCIS. From a total of 
82,703 modules queried in the entire human genome, 244 promoter loci were found to 
be associated with these 63 up-regulated genes.  Enrichment analysis (represented in 
Table 1) showed that the common framework (predicted cluster of regulating 
transcription factors) RXRF-ZF02-ZF02-PLAG-HDBP is highly enriched [336-fold] in our 
data-set, present in the promoters of RAP1GAP, SPRY4 and PDGFB genes (Kaur, Mao 
et al. 2012).   
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Figure 1.1: Venn diagram showing the results of microarray analysis of the three 
models of DCIS: MCF10.DCIS, SUM 102 and SUM 225.  
 
There are a total of 157 genes that are consistently differentially expressed in MCF10A 
vs. DCIS models. 
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Table 1:  Common framework as analyzed by the Genomatix tool.  
The numbers highlighted in yellow represent the significantly enriched promoter 
elements for the 63 upregulated genes.  Marked in red, the RXRF-ZF02-PLAG-HDBP 
framework was highly enriched on the Rap1Gap promoter (with an enrichment of 336). 
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1.4 Rap1Gap  
Rap1Gap is a member of a family of GTPase activating proteins (GAPs) that 
facilitate GTP hydrolysis of Rap1 GTPases (Raaijmakers and Bos 2009). The Rap1Gap 
gene, which lies at 1p36-p35 in the human, is conserved in many species, including 
Drosophila melanogaster, Caenorhabditis elegans, Anopheles gambia, Mus musculus, 
Rattus norvegicus and Homo sapiens (from: 
http://www.ncbi.nlm.nih.gov/homologene?term=RAP1GAP). Rap1Gap protein is 
expressed in a variety of normal human tissues.  Rap1Gap is abundantly expressed in 
the cerebral cortex, adrenal gland, salivary gland, lung, liver and gall bladder. 
(http://www.proteinatlas.org/ENSG00000076864-RAP1GAP/tissue).   Rap1Gap protein 
is also expressed in thyroid follicular cells (Tsygankova, Prendergast et al. 2007), 
pancreatic ductal cells (Zhang, Chenwei et al. 2006) and colonic epithelial cells 
(Tsygankova, Ma et al. 2010).  
  Rap1Gap is involved in a variety of cellular processes.  Some of these processes 
are proliferation, adhesion and morphogenesis (Altschuler and Ribeiro-Neto 1998, 
Asha, de Ruiter et al. 1999, Zhang, Chenwei et al. 2006). Introduction of Rap1Gap has 
been shown to cause delay in G1-S transition (Zhang, Mitra et al. 2006). In addition to 
its role in cell proliferation, Rap1Gap is involved in integrin-mediated cell adhesion 
(Caron, Self et al. 2000, Reedquist, Ross et al. 2000).  In thyroid cancer cell lines, 
silencing of Rap1Gap alters the distribution of E-cadherin, β catenin and p120 catenin 
by reducing their accumulation at adherens junctions (Tsygankova, Ma et al. 2010).  
1.4.1 Rap1Gap in Cancer  
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Rap1Gap has been investigated in epithelial solid tumors such as melanoma, 
prostate, pancreatic cancer, squamous cell carcinoma and thyroid cancer (Weiss, Biwer 
et al. 1997, Zhang, Chenwei et al. 2006, Tsygankova, Prendergast et al. 2007, Bailey, 
Kelly et al. 2009, Zheng, Gao et al. 2009, Zuo, Gandhi et al. 2010). qPCR studies in 
pancreatic cancer show that while Rap1Gap was expressed in normal pancreatic tissue, 
it was not present in pancreatic adenocarcinomas. The authors suggest that inactivation 
of Rap1Gap may not be critical to early pancreatic cancer development (Zhang, 
Chenwei et al. 2006) and may be involved in later stages of tumor progression (Zhang, 
Chenwei et al. 2006).  Similar studies in prostate cancer implicate Rap1 activation in the 
promotion of prostate cancer metastasis.  In addition, increase in Rap1 activity (or 
decrease in Rap1Gap) was observed in invasive prostate cancer cell lines, such as DU-
145, PC3 and PC3-M cell lines and that active Rap enhances migration and invasion via 
activation of integrins (Bailey, Kelly et al. 2009). Other work on Rap1Gap in melanoma, 
thyroid and squamous cell carcinoma shows that Rap1Gap loss increased cell 
proliferation, survival, migration and invasion and that loss of Rap1Gap occurs through 
epigenetic silencing and LOH (loss of heterozygosity) (Zheng, Gao et al. 2009, Zuo, 
Gandhi et al. 2010, Banerjee, Mani et al. 2011).  LOH is a common genetic event in 
many cancer types and is defined as one of the early observations of a change in 
polymorphic markers from a heterozygous state in the germline to an apparently 
homozygous state of DNA in cancer cells (Ryland, Doyle et al. 2015). Epigenetic gene 
silencing refers to non-mutational gene inactivation that can be faithfully propagated 
from precursor cells to clones of daughter cells.  The addition of methyl groups to 
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cytosine residues in CpG dinucleotides in DNA is a mechanism through which 
epigenetic silencing is achieved (Tycko 2000).  
 1.4.2 Rap1Gap: A Potential Tumor Suppressor 
Research suggests that since Rap1Gap is frequently lost in several tumor types, 
it may function as a tumor suppressor (Tsygankova, Feshchenko et al. 2004). For 
example, LOH of the Rap1Gap gene is present in a significant number of pancreatic 
tumors (Zhang, Chenwei et al. 2006).  Loss of Rap1Gap function promotes growth, 
survival and invasion of pancreatic cancer cells in vitro and in vivo (Zhang, Chenwei et 
al. 2006). In addition, studies on primary thyroid tumor cell lines show that Rap1Gap 
expression is lost at a higher frequency in more aggressive tumor types via promoter 
hypermethylation and LOH (Zuo, Gandhi et al. 2010). Studies in prostate cancer 
indicate that activation of Rap1 induced prostate cancer cell migration and invasion and 
enhanced the rate and incidence in mouse xenograft models. Re-expression of 
Rap1Gap in aggressive prostate cancer cells impaired migration and invasion (Bailey, 
Kelly et al. 2009). In squamous cell carcinoma of head and neck, Rap1Gap is shown to 
inhibit proliferation (Zhang, Mitra et al. 2006), invasion (Mitra, Goto et al. 2008) and 
progression though the cell cycle. In-vivo studies indicate that human squamous cell 
carcinoma cells transfected with Rap1Gap produced significantly smaller tumors in mice 
(Zhang, Mitra et al. 2006). In leukemia, Rap1Gap also has been shown to promote 
apoptosis (Qiu, Qi et al. 2012). Taken together, in multiple models, Rap1Gap is lost 
(epigenetic silencing or LOH) in aggressive cancer cell lines and tumors. Re-expression 
of Rap1Gap inhibits cell proliferation and passage through the cell cycle.  Experiments 
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in pancreatic cancer in-vivo mouse models indicate that introduction of Rap1Gap 
inhibits tumor formation, tumor size and metastasis (Zhang, Chenwei et al. 2006).   
Tumor suppressors serve as transducers of anti-proliferative signals and inhibit 
cell cycle progression. Tumor suppressors also exert their effects through induction of 
apoptosis and end mitotic differentiation (Weinberg 1991).  An important characteristic 
of tumor suppressor genes is that they are lost in many cancer types, such as 
melanoma, breast, small cell lung cancer, bladder cancer, retinoblastoma, colorectal 
cancer etc. (Klein 1987, Kaden, Gadi et al. 1989, Kaden, Bardwell et al. 1989).  
Rap1Gap possesses the majority of these well-studied characteristics, which suggests 
that Rap1Gap may function as a tumor suppressor. 
1.5 Rap1Gap mRNA transcripts are highly expressed in MCF10.DCIS 
 
The previous NGS results and Genomatix analysis revealed increased Rap1Gap 
transcript levels in MCF10.DCIS compared to MCF10A, thus indicating that Rap1Gap 
could be as a pivotal factor in the development of DCIS (Kaur, Mao et al. 2013).   In 
order to validate the mRNA seq analysis, qPCR (quantitative polymerase chain 
reaction) was performed on mRNA extracted from the MCF10 cell series grown in 2D. 
The MCF-7 cell line served as the appropriate positive control for initial characterization 
of Rap1Gap. This information was obtained from abstract #3840 presented at the 102nd 
AACR meeting in Orlando Florida, which indicated that Rap1Gap is highly expressed in 
MCF-7 cells. This work was done by the Meinkoth laboratory, focused on Rap1Gap in 
thyroid colon cancer cells.  As seen in Figure 1.2, mRNA expression levels in 
MCF10.DCIS are high compared to MCF10A.  However, interestingly, mRNA 
expression in SUM 102 cells is low, which is does not agree with the original mRNA seq 
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analysis. A reason for this discrepancy might be due to the passage number of SUM 
102 cells used in the initial mRNA seq analysis vs qPCR study. A repeat of the qPCR 
study is necessary to confirm the results. Table 2 depicts the mean CT (Comparative 
Threshold) values of Rap1Gap and 18S in the MCF10 progression series.   
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A. 
 
 
 
 
Table 2. Mean CT Values of Rap1Gap and 18S 
 MCF10A Neo T AT1 DCIS CA1d SUM 102 MCF-7 
Rap1Gap 30.36 32.17 32.416 28.71 29.74 33.82 27.54 
18S 15.67 16.18 15.04 15.04 15.04 15.04 15.04 
 
Figure 1.2:  Validation of transcriptome data via qPCR of Rap1Gap in MCF10 
series.   
A.  Results of Rap1Gap qPCR analysis of mRNA transcripts from the MCF10 series, 
SUM 102 and MCF-7 cultured in 2D.  18S was used to normalize Rap1Gap mRNA 
levels. Table 2 shows mean CT values of Rap1Gap and18S in the MCF10 progression 
series. 
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1.6 Rap1 
Rap1 GTPase was first discovered by Kitayama and colleagues in 1989 as a 
gene product that normalized a malignant phenotype of K-ras transformed fibroblasts 
(Kitayama, Sugimoto et al. 1989). It was discovered later that Rap1 antagonized the 
activity of Ras by competing for Raf1, a serine-threonine kinase (Bos 1998). Loss of 
function mutations in Rap1 is lethal at the larval stage in Drosophila melanogaster 
(Asha, de Ruiter et al. 1999). 
  Rap1 has two isoforms- Rap1a and Rap1b. Rap1 binds either to GTP or GDP, 
and the transition between the two states represents a molecular switch (Takai, Sasaki 
et al. 2001).  Endogenous Rap1 is activated through stimulation of various 
transmembrane receptors such as receptor tyrosine kinases, heterotrimeric G-protein 
coupled receptors, cytokine receptors and cell-cell adhesion molecules.  These indirect 
upstream activators of Rap1 were discovered after the development of the Rap1 activity 
assay, via using Ral GDS-RBD fusion proteins (Franke, Akkerman et al. 1997). Since 
Rap is located downstream of so many pathways, it is not surprising that a plethora of 
Rap1 “on“ and “off” switches are in place to fine-tune diverse signaling pathways that 
are mediated by Rap1. Figure 1.3 is a depiction of the fine-tuned diverse signaling of 
Rap1. 
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Figure 1.3:  Fine-tuned regulation of Rap1. 
 Image taken with permission from:  Nature Reviews Molecular Cell Biology 2, 369-
377 (May 2001) 
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1.6.1“ON”-The activators of Rap1- the GEFs 
GEFS, which are guanine nucleotide exchange factors, facilitate the release of 
GDP (guanosine diphosphate) allowing Rap1 to bind to GTP.  C3G (Crk SH3-domain 
binding guanine nucleotide releasing factor) was the first Rap1 specific GEF to be 
identified.  It specifically mediates Rap1 activation induced by receptor tyrosine kinases 
such as those for PDGF and IFNα, the T-cell receptor complex, and ephrin kinase 
(Gotoh, Hattori et al. 1995).   
Activation of Rap1 through cAMP was initially thought to indicate the possible 
involvement of protein kinase A, a target of cAMP.  This observation eventually led to 
the identification of Epac1 (exchange protein directly activated by cAMP). Epac1 is 
activated in vitro and in vivo by direct binding of cAMP (de Rooij, Zwartkruis et al. 1998, 
Kawasaki, Springett et al. 1998). In addition to C3G and Epac1, two other types of 
GEFs have been characterized; these are the CD-GEFs and the PDZ GEFs (Gloerich 
and Bos 2011). 
1.6.2 “OFF”- The deactivators of Rap1: the GAPs 
Two families of Rap1-specific GAPs sharing a catalytic GAP-related domain 
(GRD) have been identified.   These are the RapGaps and the SPA-1 family of proteins 
(Bos, de Rooij et al. 2001).  GAPs enhance the intrinsic GTPase activity of Rap1 to 
hydrolyze bound GTP to GDP. Proteins bearing the GRD are conserved in C. elegans 
and D. melanogaster, extending to mammals.  Figure 1.4 shows the different GAPs and 
their domains. Rap1Gap was the first Rap1 specific GAP to be isolated (Polakis, 
Rubinfeld et al. 1991). 
1.6.3 The Roles of Rap1  
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Rap1 has been shown to be activated in response to various growth factors, 
cytokines and chemokines that act on receptor tyrosine kinases and G-protein couple 
receptors (Bos, de Rooij et al. 2001).  
Initial studies following the discovery of Rap1 showed that a dominant active 
Rap1 mutant (Rap1V12) attenuated Ras-mediated ERK activation, probably via 
competitive interference with c-Raf activation by Ras (Cook, Rubinfeld et al. 1993, Hu, 
Kariya et al. 1997).  Subsequent studies have indicated that the MAPK-related signaling 
pathways controlled by Ras and Rap1 may be spatially and temporally separated 
(Mochizuki, Ohba et al. 1999, Zhu, Qin et al. 2002, Ohba, Kurokawa et al. 2003). 
Rap1 plays an important role in the regulation of cell-cell adhesion.  Functional 
studies on Rap1 in testes of Drosophila melanogaster have shown that Rap1 signaling 
regulates morphogenic processes through the proper positioning of adherens junctions 
(Knox and Brown 2002, Wang, Singh et al. 2006). These results were corroborated by 
studies of Rap1 in the control of endothelial barrier function in endothelial cells (Cullere, 
Shaw et al. 2005, Fukuhara, Sakurai et al. 2005). Research has shown that while the 
activity of Rap1 plays a role in the organization of epithelial polarity in normal human 
breast epithelial cells, increased aberrant activation of Rap1, which implies lack of 
Rap1Gap control, can lead to tumor formation and progression to malignancy (Itoh, 
Nelson et al. 2007). 
In addition to cell adhesion, Rap1 plays a major role in various integrin-mediated 
biological processes, such as immunological synapse formation, macrophage 
phagocytosis, chemokine-induced adhesion and transmigration of leukocytes, 
lymphocyte and dendritic cell homing to peripheral organs, platelet adhesion and 
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aggregation, as well as adhesion of several distinct cell lines to various ECM proteins 
such as fibronectin, fibrinogen, collagen and laminin.  This is in line with studies that 
show that In normal and malignant conditions, the functional coordination of E-cadherin 
and the integrins is essential for maintenance of cellular architecture and facilitation of 
dissemination into the adjacent area of the stroma, especially during ductal branching in 
mammary gland development (Wiseman and Werb 2002). 
Rap1 regulates recycling, avidity and affinity of integrins that are associated with 
the actin cytoskeleton (Retta, Balzac et al. 2006). In human cell lines, Rap1 controls T-
cell receptor, CD31 and CD98 induced activation of α1β2 (Katagiri, Hattori et al. 2000, 
Reedquist, Ross et al. 2000, Suga, Katagiri et al. 2001, Katagiri, Hattori et al. 2002, 
Sebzda, Bracke et al. 2002), but is also required for Mn+2 or activating antibody-induced 
α1β2-mediated adhesion (de Bruyn, Rangarajan et al. 2002).  Thus, Rap1 controls 
integrin-mediated cellular functions by modulating inside-out activation processes.  
Rap1 is suggested to regulate integrin activation either directly through their polarized 
spatial distribution or through the effect of cytoskeleton dynamics (Caron 2003, Katagiri, 
Maeda et al. 2003, Bos 2005).  
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Figure 1.4: Family of Gaps. 
 Depicted here is a family of the GAPs, some of which are regulators of Rap1.  Circled 
in red is Rap1Gap, which is of interest in this dissertation. The GoLoco domain, which 
contains the conserved Asp-Gln-Arg triad, is located at the N terminus.  This domain, 
which plays a direct role in GDP binding, is conserved throughout multiple species of 
the animal kingdom.  Image taken with permission from:  Golrich, M. and Bos. J.L. 
2011. Trends Cell Biol. 2011 Oct;21(10):615-23.  
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1.7  Regulation of E-cadherin 
E-cadherin is a principal effector of cell-cell adhesion and is a critical determinant 
of tissue architecture and function in both developing and adult organisms (Wheelock 
and Johnson 2003).  Therefore, orchestration of E-cadherin functions plays an essential 
role in physiological and pathological processes. The cadherins, the hallmark of a fully 
differentiated epithelium (Wong and Gumbiner 2003), are single-pass trans-membrane 
glycoproteins characterized by a variable number of extra-cellular cadherin domains 
that mediate cell-cell adhesion in all solid tissues. In epithelia, E-cadherin is an essential 
component of the adherens junctions, which are specialized calcium-dependent 
adhesive structures required for formation and maintenance of stable cell-cell adhesion 
(Wheelock and Johnson 2003).  β-catenin interacts directly with the cadherin 
cytoplasmic tail and α-catenin binds to both β-catenin and actin, connecting the 
cadherin-catenin complex to the actin cytoskeleton (Balzac, Avolio et al. 2005).   
 E-cadherin has also been shown to behave as a tumor suppressor by inhibiting 
human mammary and prostate tumor cell invasion (Wong and Gumbiner 2003). In 
addition, a direct role of E-cadherin in the suppression of invasion has been 
demonstrated by the reversion of undifferentiated, invasive cells to a differentiated 
phenotype after the transfection of E-cadherin cDNA in cell culture models (Doki, 
Shiozaki et al. 1993). Studies have shown that the strong adhesive properties of E-
cadherin prevent cells from dissociating from other cells and migrating into the adjacent 
microenvironment. This was shown by using E-cadherin blocking antibodies, which 
increased cell invasion (Frixen, Behrens et al. 1991). However, other studies have 
shown that suppression of tumor invasion by E-cadherin would be independent of 
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adhesion itself, and that adhesion suppressive mechanism of tumor invasion is neither 
necessary nor sufficient (Wong and Gumbiner 2003) for invasion. Several 
immunohistochemical studies have reported a strong correlation between E-cadherin 
loss and the initiation and progression of tumors (Berx, Becker et al. 1998). This down-
regulation is generally due to transcriptional repression; loss of E-cadherin function by 
genetic inactivation or epigenetic silencing is a common characteristic of invasive 
carcinomas (Lombaerts, van Wezel et al. 2006). 
1.8 The role of cytoskeletal remodeling in invasion 
The cytoskeleton plays a pivotal role in the various aspects of cell physiology- 
including mitosis, cell division, volume control and cell polarity. It also receives, 
integrates and transmits both intracellular and extracellular signals. Cytoskeletal 
networks are composed of microtubules, actin and septins, which act as signaling 
processors received from the membrane (Bezanilla, Gladfelter et al. 2015).  Actin and 
vimentin will be of focus in this dissertation, since actin and vimentin re-organization 
play an important role in the process of invasion. 
1.8.1 Actin 
Actin belongs to a family of global multi-functional proteins that form 
microfilaments.  It participates in many important cellular processes such as muscle 
contraction, cell motility, cell division, polarization and cytokinesis (Doherty and 
McMahon 2008). Actin defines the “skeleton” of the cell and is responsible for the shape 
of the cell (Mattila, Batista et al. 2016) and is spatio-temporally regulated. It also has 
emerged as a key player in cellular signaling and is remodeled in order to provide force 
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and support for the cellular structures and serve as tracks for vesicle or organelle 
movement.  
In epithelial cells, actin cortical rings are present and in tight association with cell-
cell adhesions (Haynes, Srivastava et al. 2011). They are located at the inner surface of 
the baso-lateral side (Hofer, Jons et al. 1998).  During the process of invasion, cells 
may acquire EMT (epithelial to mesenchymal transition)-like characteristics.  These 
include the dissolution of cortical rings and re-organization of actin into parallel bundles 
or stress fibers and loss of epithelial cell polarity (Haynes, Srivastava et al. 2011).    
1.8.2 Vimentin 
Vimentin is a type III intermediate filament (IF) protein and is ubiquitously 
expressed in normal mesenchymal cells. Like actin, it plays a role in the maintenance of 
cellular integrity and provides resistance against stress (Satelli and Li 2011) and 
regulates adhesion by controlling the function of integrins (Ivaska, Pallari et al. 2007). 
 In the context of cancer, increased vimentin expression is observed in a variety of 
epithelial cancers and has been strongly correlated with increased tumor growth, 
invasion and poor prognosis (Satelli and Li 2011). Vimentin is also known as a 
canonical marker of EMT (epithelial to mesenchymal transition), which takes place in 
both embryogenesis and metastasis (Hay 2005); expression levels correlate with 
mesenchymal cell shape and motility (Mendez, Kojima et al. 2010). Studies in breast 
cancer show that vimentin expression is elevated in several aggressive breast cancer 
cell lines (Gilles, Polette et al. 2003) and is strongly correlated with increased migration 
and invasion of breast cancer cells (Gilles, Polette et al. 2003, Korsching, Packeisen et 
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al. 2005). Other studies have documented over expression of vimentin in breast cancer 
tissues (Kokkinos, Wafai et al. 2007).  
1.9 3D Overlay Culture: An overview 
The mammary epithelium is organized into two layers: the luminal epithelial cells 
that make milk proteins, and the highly contractile basal, or myoepithelial, cells 
surrounding the luminal cells. The myoepithelial cells contact the basal lamina, and 
regulate the function and polarity of the apical cells. Much evidence supports the idea 
that adhesion to the basal lamina helps to establish cellular polarity (Barcellos-Hoff, 
Aggeler et al. 1989, Bissell and Ram 1989). Cell–matrix adhesion regulates mammary 
cell structure and function in culture models. For example, inhibition of mammary 
epithelial cell contact with the BM (basement membrane) alters morphology, inhibits, 
survival, decreases proliferation, and inhibits differentiation (Barcellos-Hoff, Aggeler et 
al. 1989). Culturing cells on a reconstituted BM matrix or on laminin restores many of 
these functions (Streuli, Schmidhauser et al. 1995). Interaction of mammary cells with 
the ECM (extra cellular matrix) is mediated by integrins, and luminal epithelium 
expresses the α2β1, α3β1 and α6β1 heterodimers (Prince, Klinowska et al. 2002). 
Given the significant body of evidence regarding the influence of the ECM on the 
structure and function of mammary epithelial cells, it makes sense to utilize 3D overlay 
culture in this project.  It is more likely to recapitulate the in vivo milieu. In addition to 
interrogation of the effects of the ECM on structure, function and differentiation of 
epithelial cells, there are other important applications that will be highlighted at this time.  
Culture of cells on an ECM yields more physiologically relevant information about 
signaling pathways and drug efficacy. 
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  The most relevant method of culture of mammary epithelial cells in 3D in rBM 
(reconstituted basement membrane) was developed in the Brugge and Bissell 
laboratories(Debnath, Muthuswamy et al. 2003, Lee, Kenny et al. 2007). A depiction of 
the 3D culture method utilized in this dissertation work is depicted in Figure 1.5. Cells 
grown on a matrix are relatively resistant to chemotherapeutic drugs (Weaver, Lelievre 
et al. 2002) and studies from our laboratory have found that 3D overlay culture reveals a 
critical sensitivity of Ras driven breast cancer models to MEK (MAPK/ERK kinase) 
inhibitors that was absent in a 2D microenvironment (Li, Chow et al. 2010).  Additionally, 
the cross-talk between some signaling pathways is not apparent in 2D- and it is their 
growth in a 3D environment that unveils previously unknown dynamics (Wang, Weaver 
et al. 1998). Proof of this cross talk is observed in the more pronounced phenotypic 
differences between non-transformed and malignant epithelial cells cultured on rBM.  
This would be due to the interplay between multiple pathways governing epithelial cell 
polarity and organization of the structures (Petersen, Ronnov-Jessen et al. 1992, 
Debnath and Brugge 2005, Lee, Kenny et al. 2007). This phenomenon is observed in 
this project.  Evidence of differences in Src signaling in 2D and 3D environments will be 
addressed in Chapter 5.  
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Figure 1.5: 3D Overlay Culture: A method that more accurately recapitulates in 
vivo microenvironment.  
 
Epithelial cells are plated in rBM (reconstituted basement membrane) and an overlay 
added to embed the cells in a 3D matrix. When placed in a 3D environment, cells exhibit 
differences in organization of epithelial structures, gene expression profiles and protein 
expression. The 3D structures represented here simulate transformed epithelial cells 
(MCF10.DCIS). 
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1.10 ERK/MAPK 
The MAPK (mitogen activated protein kinase) pathway is widely studied. The 
classical MAPK pathway consists of RAS, RAF, MEK and ERK. It relays a cascade of 
signals which regulate the processes of proliferation, differentiation, growth and 
migration (Dhillon, Hagan et al. 2007).  Ligand mediated activation of receptor mediated 
kinases triggers guanosine triphosphate (GTP) loading of Ras GTPase, which then 
recruits Raf kinases to the plasma membrane for activation. Raf then activates MEK1/2, 
which in turn activates ERK1/2 (Cargnello and Roux 2011).  ERK1/2 activation has 
been observed in a wide variety of cancers and is closely associated with cancer 
development, migration, invasion and metastasis (Park, Jung et al. 2011).  
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CHAPTER 2: METHODS 
2.1 Cell Culture:  2D and 3D 
MCF10A series of cells were maintained as monolayers in 2D culture at 37°C, 
5% CO2 in growth medium: DMEM/F12 (without phenol red) containing 5% horse 
serum, 20 ng/ml epidermal growth factor, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 50 
U/ml penicillin, and 50 μg/ml streptomycin. For 3D culture, a trypsinized single cell 
suspension in a 4-ml volume of the assay medium (DMEM/F12 containing 2% horse 
serum, 5 ng/ml EGF, 0.5 µg/ml hydrocortisone, 10 µg/ml insulin, 50 U/ml penicillin, 50 
µg/ml streptomycin, and supplemented with 2% (v/v) of Cultrex) were carefully loaded 
on top of the rBM, and will be cultured at 37°C and 5% CO2, with the medium being 
changed every 4 days. 3D structures were fixed or harvested after 8 days of growth.  
2.2 Retroviral Infection for shRNA Knockdown 
Targeted cell lines for Rap1Gap knockdown were MCF10.DCIS, MCF10.Ca1D, 
and T47-D breast cancer cells.  HEK293T cells were maintained at 37°C in DMEM 
containing 10% FBS, 50 U/ml penicillin, 50 µg/ml streptomycin and supplemented with 4 
mM l-glutamine, and 1 mM sodium pyruvate until 90% confluent. For transfection, the 
medium was changed to omit the antibiotics. Then, the cells were triply transfected with 
equal amounts of the retrovirus construct, pVPack-GP plasmid, and pVPack-VSV-G 
plasmid using Lipofectamine 2000 reagent according to the manufacturer's instructions. 
The medium was changed 6 hours after transfection, and the cells were cultured at 
37°C for 16 hours when extensive expression of the reporter dsRed proteins could be 
monitored by fluorescent microscopy. The medium was changed and the cells were 
cultured at 30°C for 24 hours for the production of retroviruses. The virus broth was 
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pipetted and centrifuged for 5 minutes at 200g to remove cell debris. Fresh medium was 
added and the HEK293 cells were continued to be cultured for 24 hours at 30°C to 
harvest a second batch of virus broth. 
The supernatant broth containing viruses was supplemented with polybrene at a 
final concentration of 12 µg/ml by the addition of a 4 mg/ml polybrene stock solution.  
Cells were trypsinized, centrifuged, and resuspended in growth medium to form single 
cell suspensions at a concentration of 2 x 106 cells/ml. The cell suspensions were mixed 
(3:1 v/v ratio) with virus mixture, plated onto tissue culture dishes at low starting 
confluence (typically ~5%), and cultured at 37°C.  The next day, the medium was 
changed, and the cells were subjected to a second round of infection using the second 
batch of viruses as described above. On the third day, the medium was changed again, 
and the culture continued. Virus transduction efficiency was checked using confocal 
fluorescent microscopy. The infection efficiency was ≥ 90% based on fluorescence. 
2.3 Transient Re-expression of GFP-Rap1Gap 
The gold standard control for knockdown experiments is re-expression of the 
protein of interest. Originally, the plan was to virally infect the DCIS Rap1Gap shRNA 
cell lines with GFP-Rap1Gap. Many attempts were made to clone GFP-Rap1Gap into 
various vectors. Restriction digests and ligation experiments were repeated, and sizes 
of the fragments were confirmed to confirm proper ligation.  Repeated transformation 
experiments in competent bacterial cells yielded 2-3 colonies.  Restriction digests of 
plasmid DNA isolated from the colonies did not confirm the presence of the full insert.  
Different competent cells and different ligation reagents were also used to troubleshoot. 
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After 8 months of trial and error, the procedure had to be abandoned and we decided to 
proceed with the transient transfection. 
Targeted cell lines for transient overexpression of GFP-Rap1Gap were MCF10A, 
DCIS.Rap1Gap shRNA and SUM 102. Target cell lines were cultured until 80% 
confluent on 35mm dishes.  On the day of transfection, media were changed and cells 
were given antibiotic free medium.  Plasmid DNA and Lipofectamine 2000 were mixed 
in Optimem and allowed to incubate at room temperature for 5 mins.  Both the solutions 
were mixed together and incubated for 20 mins at room temperature.  The mixture was 
then pipetted and added to the cells.  Cells were incubated at 37o C for 6 h.  The 
medium were changed and fluorescence was monitored after 48 h. 
2.4 Immunofluorescence 
Cells growing on rBM were cultured in 35mm dishes.  To fix structures, cultures 
were briefly washed with pre-warmed PBS and incubated in 4% paraformaldehyde, pH 
7.5 in PBS for 30 minutes at room temperature. The fixation was quenched by three 
washes with 0.75% glycine in PBS. Then, the cellular structures were permeabilized 
with 0.5% Triton X-100 (v/v) in PBS for 10 minutes and blocked with a 1-hour incubation 
in immunofluorescence (IF) buffer: 130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4, 
0.1% BSA (v/v), 0.2% Triton X-100 (v/v), and 0.05% Tween-20 (v/v), pH 7.5. Structures 
were incubated at 4°C with primary antibody in IF buffer overnight in a humidified 
chamber. After washing three times with IF buffer, the 3D structures were further 
incubated with the fluorescent conjugated secondary antibodies together with other 
fluorescent cellular staining reagents (e.g., DAPI, Alexa Fluor-568 phalloidin or Alexa 
Fluor-488) at room temperature for 2 hours.  After three washes with IF buffer, the 3D 
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structures were imaged with a confocal microscope (780; Zeiss, Göttingen, Germany) 
as described previously (Yang and Mattingly 2006). 
2.5 3D Culture Experiments 
Growth of cells in 3D rBM overlay culture (Cultrex, from Trevigen) was assayed 
by measurement of volume of structures formed. Fixed cells were imaged with an LSM 
780 confocal microscope (Carl Zeiss GmbH, Jena, Germany) using 10x or 63x objective 
dipping lenses. Tile-scan mode was used to obtain a 2x2 or 4x4 phase contrast tile 
image.  
2.6 Morphometric Analysis of Outgrowths of 3D Structures 
Differential interference contrast (DIC) images of three random fields at 20x 
magnification were used to measure the outgrowths. Outgrowths were defined as small 
thorn like structures emanating from the center of the main structure. Two blinded 
individuals counted the outgrowths in the images captured at 20x magnification in 
accordance with the following parameters:  outgrowths >0.5 mm in length and width 
were counted. Connections  and branches in between the structures were not counted.  
Statistical analysis was performed by using one-way ANOVA by GraphPad Prism 
software.  
2.7 Cell Proliferation Assays 
Ten-thousand MCF10.DCIS-dsRed control and MCF10.DCIS-Rap1Gap shRNA 
cells were plated in 60-mm dishes.  At 48, 96 and 144 h time points, attached cells were 
trypsinized and centrifuged at 1000 g.  After resuspension, cells were counted with a 
hemocytometer via trypan blue exclusion, a common method used to check cell viability 
and facilitate counting. Live cells have intact membranes that prevent trypan blue dye 
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from entering. Results were recorded as cell number. Experiments were repeated three 
times under same conditions. 
2.8 Lysate Preparation for Immunoblotting 
To obtain sufficient material for immunblotting from 3D rBM cultures, the overlay 
culture process was performed on 60-mm culture dishes. The cultures were briefly 
washed with ice-cold PBS (phosphate buffered saline).  3D structures were then 
scraped in ice-cold PBS + 5 mM EDTA supplemented with protease and phosphatase 
inhibitors and rocked on ice for two hours.  3D structures were centrifuged for 3 min at 
1000 g, resuspended and rocked on ice for 30 mins to further dissolve the Cultrex.  
After one wash with PBS, the cells were solubilized in a buffer designed for both lysis: 
50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 10 mM sodium pyrophosphate, 2 mM EDTA, 
1% (v/v) Nonidet P40, 1% (v/v) 2-mercaptoethanol, 10% (v/v) glycerol, 2% (w/v) SDS, 
50 mM sodium fluoride, 0.2 mM sodium orthovanadate, 0.005% (w/v) bromphenol blue, 
and supplemented with protease inhibitor mixtures according to the manufacturer's 
instructions. The cell lysates were subjected to brief sonication and heated in 100°C for 
5 min.  Thirty micrograms of protein were loaded onto 8-12% SDS-polyacrylamide gels 
for electrophoresis, ran at 90 V for 2 h. The proteins from the gel were transferred onto 
nitrocellulose membrane, blocked with 2% milk solution, and probed for specific target 
proteins with corresponding antibodies. 
2.9 Preparation of Cytosolic and Nuclear Fractions 
Cells were scraped into extraction buffer containing 10 mM Hepes (pH 7.4), 5 
mM MgCl2, 1 mM EDTA, 1 mM EGTA, 0.1% NP40 (v/v) and protease inhibitor cocktail 
and lysed by using a 26 gauge needle.  The lysate was centrifuged for 5 min at 1000 x g 
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to yield supernatant (cytosolic fraction) and pellet (nuclear fraction and any unbroken 
cells) which was re-suspended in RIPA buffer and sonicated.                                                                                                                                                  
2.10 Rap1 Activity Assay 
Rap1 activity assays were performed according to the instructions of the 
manufacturer (Millipore). Whole cell lysates were prepared by incubating the cells in ice-
cold lysis buffer (50 mmol/L Tris-HCl (pH 7.4), 0.5 mol/L NaCl, 1% NP40, 2.5 mmol/L 
MgCl2, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and 10% glycerol).  Lysates were 
centrifuged at 14,000 × g for 5 minutes at 4°C. The supernatant was removed and 
assayed for protein concentration using the Bio-Rad protein assay.  
Thirty microliters of Ral GDS-RBD agarose were added to each tube containing 
0.5 mL cell extract and rotated for 45 minutes at 4°C. Pellet beads were collected by 
centrifugation (10 seconds, 14,000 × g) and washed thrice with lysis buffer. The beads 
were resuspended in 20 μL of 2× Laemmli buffer followed by boiling for 5 minutes. 
Samples were run on 15% gel, transferred, and blotted for Rap1. Light exposures of 
immunoblot bands for the activity assay and other immunoblots were selected to that 
the bands were not saturated. The blots were quantified using densitometry via Multi 
Gauge© software. 
2.11 Invasion Assays 
Thirty thousand cells of MCF10.DCIS and MCF10.DCIS Rap1Gap shRNA were 
seeded in serum-free media on BD (Franklin Lakes, NJ, USA) cell culture inserts (8 µm 
pore size) pre-coated with Cultrex® (2 mg/ml) and allowed to invade toward media 
supplemented with 5% horse serum for 24h. Invading cells were stained and mounted 
on slides using the Dif-Quik kit (Thermofisher). Cells were visualized using a Zeiss 
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Axiovert microscope, and were counted using ImageJ software. Data were collected 
from at least three independent experiments performed in triplicate.  
2.12 Live-cell Proteolysis Assays 
35-mm petri dishes were coated with 50 µl of rBM containing 25 mg/ml of DQ-
collagen IV (2.5%) (Invitrogen Life Technologies) and placed in a 37 °C incubator for 15 
min to solidify. One thousand cells were plated on top of the rBM and incubated at 37 
°C for 30–60 min until they attached. The overlay was added to the cells and cultured 
for 8 days. Overlay is defined as assay media with lower concentration of the same 
ingredients as phenol red free maintenance media, with 2% horse serum and 2% 
Cultrex® (v/v). Phenol red free media is preferred since phenol red interferes with 
fluorescence detection.  Degradation products of DQ collagen IV (green) were imaged 
with a Zeiss LSM 780 META NLO confocal microscope at 488 nm using a 20x and a 
63x water immersion objectives.  Z- stack images were captured and used to make 3D 
reconstructions of the spheroids using Volocity 4.2.0 software (Perkin Elmer, Waltham, 
MA). Using the Z-stack, the extent to which the cells invaded into the rBM was 
assessed by the presence of fluorescent cleavage products. 
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CHAPTER 3: RESULTS 
3.1. Rap1Gap protein is highly expressed in MCF10.DCIS in both 2D and 3D 
conditions 
Previous studies aimed to determine specific gene expression changes common 
to three models of DCIS in comparison to MCF10A cells as a model of normal human 
mammary epithelium. mRNA seq results showed that Rap1Gap was up-regulated in all 
three models of DCIS, compared to MCF10A cells. Multiple studies have focused on 
loss of Rap1Gap in acquisition of invasive phenotype in a variety of tissue types. This 
dissertation is focused on the loss of Rap1Gap in breast cancer. 
Assessment of Rap1Gap protein expression in the MCF10 progression series 
was performed in order to validate the initial transcriptome analysis (Fig 1.1). The 
immunoblots in Figure 3.1 are of Rap1Gap protein expression in the MCF10 
progression series in lysates prepared from 3D and 2D environments. The immunoblot 
in Panel A is of Rap1Gap levels from lysates prepared from cells grown in 3D. MCF10A 
cells express low levels of Rap1Gap; MCF10.DCIS expressed higher levels, and 
MCF10.CA1d, a model of invasive breast cancer, expressed an intermediate level.  The 
immunoblot in panel B (Rap1Gap levels in lysates harvested from 2D culture) depicts a 
similar trend. Rap1Gap protein levels in MCF10.Neo T cells grown in 3D are 
significantly higher than lysates grown in 2D environment, but the reason for this 
difference is not known. For initial standardization of the antibody for Rap1Gap, lysates 
of MCF-7 cells were used as a positive control for immunoblotting [see published AACR 
abstract (#3840, 2011) from Prof. Judy Meinkoth], Thus, Rap1Gap protein levels are 
low in MCF10A cells, increased in MCF10.DCIS and reduced in MCF10.CA1d cells. 
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Figure 3.1: Rap1Gap protein is highly expressed in MCF10.DCIS, with reduced 
expression in MCF10.Ca1D, a model of human invasive breast cancer. 
 
 
A.  Lysates were prepared after 8 days of culture in rBM.  Immunoblotting was 
performed using a polyclonal antibody against Rap1Gap. The molecular weight of 
Rap1Gap is 95 kDa.  β-tubulin was used as a loading control.  B. Lysates prepared from 
cells grown in 2D after 3 days in culture.  MCF-7 cells were used as a positive control.  
β-tubulin served as a loading control. Results are representative of 3 independent 
experiments.   
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3.2 Rap1Gap is abundantly expressed in luminal hormone responsive cell lines 
yet weakly expressed in mesenchymal and metastatic breast cancer cell lines 
As mentioned previously, multiple studies have demonstrated loss of Rap1Gap 
as a characteristic of acquisition of invasive phenotype. For example Rap1Gap is lost in 
aggressive pancreatic and thyroid cancers (Zhang, Chenwei et al. 2006, Zuo, Gandhi et 
al. 2010).  Basal breast cancer cell- lines express characteristics that are reflective of 
invasive metastatic phenotype (Perou, Jeffrey et al. 1999, Chung, Bernard et al. 2002). 
Rap1Gap is also highly expressed in differentiated epithelial tissues (Zhang, Mitra et al. 
2006, Tsygankova, Ma et al. 2010). Luminal breast cancer cell lines, which are distinct 
from basal breast cancer cell lines, preferentially express genes that are associated with 
a differentiated phenotype (Beck, Zerler et al. 2001, Feldman, Sementchenko et al. 
2003, Charafe-Jauffret, Ginestier et al. 2006). Hence, we hypothesized that Rap1Gap 
may be lost in invasive, metastatic breast cancer cell lines and highly expressed in 
luminal breast cancer cell lines. 
 In Figure 3.2, the results show that Rap1Gap is expressed at higher levels in 
luminal cell lines (MCF-7 and T47-D), compared to lower expression in the basal breast 
cancer cell lines (MDA-MB-231, Hs578t and BT549).  In the two DCIS lines derived 
from patients (SUM 225 and SUM 102), Rap1Gap levels are strikingly different.  SUM 
225, a cell line expressing luminal markers (Behbod, Kittrell et al. 2009) and derived 
from a chest wall recurrence abundantly expresses Rap1Gap; SUM 102 cells of basal 
type derived from a DCIS with micro-invasion (Ethier, Mahacek et al. 1993, Ethier 
1996), expresses lower levels of Rap1Gap, which is in agreement with the qPCR data 
in Figure 1.2. The stark differences in Rap1Gap expression in SUM 225 and SUM 102 
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potentially address the heterogeneity seen in DCIS patients. These potential differences 
might be due to transcriptional and/or translational regulation.  For example, qPCR 
analysis of Rap1Gap reveals low Rap1Gap transcripts in SUM 102 cells, potentially 
leading to low protein levels.  SUM 225 cells express higher levels of Rap1Gap, both at 
the mRNA and protein levels. This might be due to either concomitant synthesis of more 
protein or post-translational stabilization of existing protein. 
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Figure 3.2: Rap1Gap expression in breast cancer cell lines. 
 
Lysates were prepared from 3D cultures grown for 8 days on rBM, subject to SDS-
PAGE and immunoblotting using anti-Rap1Gap antibodies.  β-tubulin is a loading 
control.  Results are representative of three independent experiments. Luminal cell lines 
are MCF-7 and T47-D; BT549, MDA-MB-231 and Hs578t are basal cell lines; SUM 225 
and SUM 102 are DCIS cell lines.  
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3.3. Rap1Gap is found in the nuclear and cytosolic fractions in the MCF10 series 
Rap1Gap is known to play a role in the maintenance of adherens junctions and 
cell-ECM attachments (Tsygankova, Ma et al. 2010) characterizing it as a cytosolic 
protein.  Staining of Rap1Gap in colon and thyroid tissue samples 
(http://www.proteinatlas.org/ENSG00000076864-RAP1GAP/tissue) also indicate that 
Rap1Gap is located in the cytosol. Images from Protein Atlas were reviewed and 
confirmed that Rap1Gap is present in the cytosol. The database mentioned above did 
not mention evidence of Rap1Gap nuclear staining. Further analysis by a trained 
pathologist is necessary to confirm the presence of Rap1Gap in the nucleus. To 
determine the localization of Rap1Gap in the MCF10 series, cell fractionation 
experiments were performed on lysates prepared from cells grown in 2D cultures. 
Interestingly, as seen in Figure 3.3, Rap1Gap is found in both cytosolic and nuclear 
fractions.   
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Figure 3.3: Rap1Gap is found in the cytosolic and nuclear fractions.  
 
Cells were grown in 2D for 4 days. Cytosolic and nuclear fractions were processed 
according to protocol described in the methods. Both fractions were subject to SDS-
PAGE and immunoblotted for Rap1Gap, tubulin and H4 (Histone 4). MCF-7 serves as a 
positive control.  β-Tubulin and H4 were used as controls for loading and to show proper 
separation of cytosol and nuclear compartments of the lysate respectively.  
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3.4 Rap1Gap knock down in MCF10.DCIS transforms cell morphology from 
epithelial to fibroblastic phenotype 
Previously, it was observed that Rap1Gap was significantly up-regulated in 
MCF10.DCIS and is reduced in MCF10.CA1D cells. Breast cancer cell lines with 
mesenchymal characteristics express very low levels of Rap1Gap. Hence, we 
hypothesized that knocking down Rap1Gap would confer mesenchymal characteristics 
in DCIS. This would include transformation to spindle shaped cells and invasive 
phenotype.  Lentiviral knockdown experiments with two separate shRNA sequences; 
(TTGGTGTGTGAAGACGTCA (kd1) and TCTTCTCACTCAAGTACGA (kd2) were 
performed. 
Panel A in Figure 3.4 shows MCF10.DCIS cells infected with pSIREN dsRed 
lentiviral control (Con) or shRNA 1 (kd1) and 2 (kd2). DCIS cells have an epithelial 
phenotype, with wide cell bodies and some cell-cell contacts.  Knockdown of Rap1Gap 
in DCIS transforms cellular shape to long and spindle like, with less frequent cell-cell 
contacts. Panel B is an immunoblot showing robust knockdown of Rap1Gap with two 
separate shRNA sequences. 
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Figure 3.4: Rap1Gap silencing in MCF10.DCIS transforms cell morphology from 
epithelial to fibroblastic phenotype.    
 
MCF10.DCIS cells infected with pSIREN dsRed control (Con) or Rap1Gap shRNA (kd1 
and kd2) and were cultured for 3 days in 2D.  A. Live Images were taken at 20x 
magnification. Scale bar, 50 µm. B. Immunoblot of Rap1Gap knockdown in 
MCF10.DCIS cells with two separate shRNA sequences, compared to the lentiviral 
control. 
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3.5 Silencing of Rap1Gap in MCF0. DCIS leads to increase in cell proliferation 
Previous studies have shown that Rap1Gap controls cell proliferation                    
(Wang, Zhang et al. 2014) and may have tumor suppressor properties.  Therefore, in 
the context of breast cancer, Rap1Gap may regulate cell proliferation. We hypothesized 
that that silencing of Rap1Gap may cause increased proliferation.  Ten thousand cells 
were plated in triplicate for termination at 48, 96 and 144 h time points.. Here, we show 
that DCIS cells devoid of Rap1Gap proliferate at a higher rate. As seen in Figure 3.6, at 
48 h time point, there is little difference in cell number in the control line vs. the DCIS 
cells transduced with the Rap1Gap shRNA.  By 96 h (4 days), the differences in 
increase in proliferation are more evident.  At 6 days, in both knockdown lines, mean 
cell numbers culminate at 140,000 cells vs. the control line, which reached 40,000 cells 
when the experiment was terminated.  We speculate that there is little difference in the 
cell proliferation between the control cells vs. the DCIS shRNA cells when plated at a 
low density.  As cells continue proliferating, the increased density of cells might increase 
the proliferation rate of the cells with Rap1Gap knockdown, which is reflected at 96 and 
144 h time points.  Loss of contact inhibition is less likely to be factor, since the cell 
density did not reach >100% confluency after 6 days of culture.  Thus, silencing of 
Rap1Gap in MCF10.DCIS causes increased cell proliferation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  
  51 
 
 
 
Figure 3.5: Rap1Gap silencing in MCF10.DCIS leads to increase in cell 
proliferation.  
Ten thousand cells were plated and allowed to grow for 48, 96 and 144 h in 2D 
conditions. Cell numbers were determined by trypan blue exclusion and manual 
counting on a hemocytometer. Data are the mean SEM of triplicate samples and are 
representative of three independent experiments. 
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3.6 Rap1Gap silencing leads to the appearance of invasive outgrowths.  
In a 2D environment, MCF10.DCIS cells have an epithelial phenotype, 
characterized by wide cell bodies.  Under the same conditions, MCF10.DCIS Rap1Gap 
shRNA cells acquire a spindle shaped morphology (Figure 3.4).  When grown in rBM, 
MCF10.DCIS, cells form dense dysplastic structures, reminiscent of DCIS in patients. 
We hypothesized that MCF10.DCIS Rap1Gap shRNA cells, when grown in rBM would 
exhibit the appearance of outgrowths, a characteristic of invasive phenotype.  
MCF10.DCIS lentiviral control and MCF10.DCIS shRNA cells were grown in 3D for 8 
days and cells were imaged live. We show that the morphology of 3D structures of 
MCF10.DCIS Rap1Gap shRNA is strikingly different.  These structures are no longer 
dense, and form multicellular invasive outgrowths.  Additionally, these structures are 
much bigger and appear more disorganized. Figures 3.6.1 and 3.6.2 show the 
morphology of DCIS Rap1Gap shRNA cells at 20x and 63x magnification. Figure 3.6.3 
panel A shows representative 4x4 DIC images used to quantify the outgrowths.  Panel 
B is the results of the outgrowth analysis. The purpose of the quantification was to 
ensure that the appearance of outgrowths is an effect of Rap1Gap silencing. Some 
outgrowths were observed in the control.  The p value of 0.0012 means that the 
differences in the number of invasive outgrowths are significant. Thus silencing of 
Rap1Gap in MCF10.DCIS induces the appearance of outgrowths, a characteristic of 
invasive phenotype. 
  
  53 
 
 
Figure 3.6.1:  Rap1Gap silencing leads to appearance of invasive outgrowths. 
 
Cells were grown in 3D for 8 days and imaged live.  DIC (Differential Interference 
Contrast) images with fluorescent overlay of non-infected MCF10.DCIS, lentiviral 
control, kd1, kd2. Images were taken at 20x magnification. Scale bar, 50 µm. Images 
are representative of at least three independent experiments. 
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Figure 3.6.2:  Rap1Gap silencing leads to appearance of invasive outgrowths. 
 
Cells were cultured in 3D for 8 days to allow growth of structures.  Structures were 
imaged live. DIC images (top) are side-by-side comparisons of non-infected DCIS vs. 
lentiviral control at 63x magnification. The images in the middle and bottom rows 
represent 20x and 63x of same structures side by side.  Red squares of outgrowths on 
the left show regions of interest and are magnified at 63x magnification on the right. 
Scale bar, 50 µm. 
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Figure 3.6.3: Analysis of Outgrowths. 
 After culture in rBM for 8 days, DIC images of live 3D structures, consisting of 16 
contiguous fields were taken at 20x magnification. The bar graph represents number of 
outgrowths per field (mean + SEM from 3 independent experiments).  Outgrowths were 
counted by two blinded individuals according to parameters described in the results.  
Statistical analysis was performed using one-way ANOVA. 
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3.7 Lentiviral silencing of Rap1Gap in MCF10.DCIS leads to reduction of                 
E- cadherin protein levels and breakdown of adherens junctions 
E-cadherin is an important component of adherens junctions, which in some 
cases are lost during the transition to an invasive phenotype (Thompson, Torri et al. 
1994). One characteristic of invasive breast cancer is reduction in E-cadherin and 
breakdown of adherens junctions. We hypothesized that reduction in E-cadherin and 
concomitant breakdown of adherens junctions may be a consequence of Rap1Gap 
knockdown, via Rap1 deregulation (Balzac, Avolio et al. 2005). In a 2D environment, 
DCIS cells containing the Rap1Gap shRNA plasmid acquire a spindle shaped 
morphology compared to the lentiviral control (Figure 3.4).  
Cells were grown in 3D for 8 days, fixed and stained for E-cadherin in order to 
visualize adherens junctions. To confirm reduction in E-cadherin protein levels, 
immunoblotting was performed.  As seen in Figure 3.7 panel A, adherens junctions are 
visible in the lentiviral control (red, stained for E-cadherin). The immunoblot in Panel B 
shows robust expression of E-cadherin in the control, with significant reduction in the 
knockdown lines (kd1 and kd2).  Two exposures of E-cadherin are shown to emphasize 
that this protein is reduced, not lost. GAPDH was used as a loading control to confirm 
equal protein loading. Thus, lentiviral silencing of Rap1Gap leads to reduction of E-
cadherin levels and breakdown of adherens junctions. 
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Figure 3.7: Rap1Gap lentiviral silencing leads to reduction of E-cadherin protein 
levels and breakdown of adherens junctions.  
 
A. Cells were cultured in 3D for 8 days and fixed. DCIS lentiviral control and DCIS 
Rap1Gap shRNA cells were grown on rBM for 8 days and fixed.   Images are four 
contiguous fields, taken at equatorial position. Red (E-cadherin) is Far Red, pseudo-
colored. DAPI represents fluorescent detection of DNA. Images were taken at 63x 
magnification. Scale bar, 150 µm. B. Cells were grown in 3D for 8 days and harvested.  
Lysates were subjected to SDS-PAGE and immunoblotting for E-cadherin and GAPDH 
(loading control). Images are representative of three independent experiments. 
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3.8 Lentiviral silencing of Rap1Gap in DCIS leads to cytoskeletal remodeling and 
vimentin reorganization 
Remodeling of the cytoskeleton is a significant part of the invasion process and is 
carefully orchestrated (Yamaguchi and Condeelis 2007, Mouneimne, Hansen et al. 
2012).  We had observed the appearance of invasive outgrowths in DCIS-Rap1Gap 
shRNA cells (Figure 3.6.2, red squares), and thus we hypothesized that they would 
indicate a significant change in the organization of the actin cytoskeleton.  Cells were 
grown in rBM for 8 days, then fixed and structures were stained for F-actin. As seen in 
Figure 3.8.1, fluorescent probe detection of filamentous actin reveals significant 
changes in actin cytoskeleton reorganization.  Cortical rings, which are typically present 
in MCF10.DCIS, are not present in majority of the structures with the Rap1Gap shRNA 
(Figure 3.8.1, Figure 3.8.2).  
 Vimentin is a well–studied member of the family of the intermediate proteins.  It 
has been well established that vimentin plays a role in the process of invasion. Hence,  
vimentin reorganization may be part of the cytoskeletal reorganization. Cells were 
seeded in 3D for 8 days, fixed, and stained with vimentin antibody. As observed in 
Figure 3.8.3, in the lentiviral control cells, vimentin is apparently closely associated with 
F-actin. However, it appears that brighter staining of vimentin was observed in the 
center of the structures in the kd2. The brighter staining in the DCIS Rap1Gap shRNA 
cells might signify either higher expression in certain areas of the structure or more 
concentration of the protein in the center of the structure.  Thus, silencing of Rap1Gap 
in MCF10.DCIS causes F-actin and vimentin organization. 
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Figure 3.8.1: Lentiviral silencing of Rap1Gap in DCIS leads to cytoskeletal 
remodeling. 
 
Cells were grown in rBM for 8 days and fixed. Fluorescent probe detection of 
filamentous actin (F-actin, green) and nuclei (blue) in the lentiviral control and kd1 and 
kd2 lines that have silenced Rap1Gap expression. Images, taken at 63x magnification, 
are collapsed z stacks of overlaid green and blue channels. Images are representative 
of at least 3 independent experiments. Scale bar, 50 µm.  
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Figure 3.8.2: Lentiviral silencing of Rap1Gap in DCIS leads to cytoskeletal 
remodeling. 
 
Fluorescent probe detection of filamentous actin (F-actin, green).  Image, taken at 63x 
magnification is an expanded image of the kd1, (middle image, top panel of Figure 
3.8.1) to emphasize the presence of F-actin stress fibers.  The white arrows point to the 
stress fibers in the outgrowths. Size bar represents 50 μm. 
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Figure 3.8.3:  Rap1Gap lentiviral silencing in DCIS leads to vimentin 
reorganization.  
 
3D structures were fixed after 8 days of culture. Then, the structures were stained for 
filamentous actin (green), vimentin (magenta) and nuclei (blue).  Images, taken at 20x 
magnification, are collapsed z stacks. Size bar represents 50 µm. Images are 
representative of 2 independent experiments (total of 4 images). 
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 3.9 Silencing of Rap1Gap in MCF10.DCIS leads to enhanced invasion 
Cytoskeleton remodeling is a significant part of the invasion process and is 
carefully orchestrated (Yamaguchi and Condeelis 2007, Mouneimne, Hansen et al. 
2012).  The appearance of invasive outgrowths in DCIS-Rap1Gap shRNA cells were 
observed, and we hypothesized that they would indicate a significant change in the 
organization of the actin cytoskeleton, leading to invasion.  
  Invasion assays were carried out. MCF10.DCIS control and MCF10.DCIS 
Rap1Gap shRNA cells were serum starved overnight.  Thirty thousand cells were 
seeded and allowed to invade through the membrane for 24 h.  Cells were fixed and 
stained blue. Figure 3.9 shows dramatic increase in invasion by the DCIS knockdown 
cells through the membrane when compared to the control.  The graph in panel B 
depicts mean number of invaded cells per field. Statistical analysis was done using one-
way ANOVA, p ≤ 0.05. 
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Figure 3.9: Silencing of Rap1Gap in MCF10.DCIS leads to enhanced invasion.  
 
A. Cells were allowed to invade through an 8 um pore membrane for 24 h and fixed and 
stained blue. Images, taken at 20x magnification are representative of 15 images per 
triplicate, per condition, per experiment.     B. Bar graph represents mean number of 
invaded cells. Error bars represent standard error of the mean. Data set is the mean of 
4 independent experiments. Statistical analysis was done using one way ANOVA.   
B 
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3.10 Lentiviral silencing of Rap1Gap leads to increased collagen IV degradation 
Silencing of Rap1Gap resulted in the progression of DCIS to an invasive 
phenotype. This was characterized by the appearance of multicellular outgrowths 
(Figure 3.6), significant remodeling of actin cytoskeleton and vimentin (Figure 3.8), and 
increase in invasion (Figure 3.9). We hypothesized that invasive structures may exhibit 
an increase in DQ collagen degradation.  
 Cells were grown in 3D for 8 days in rBM supplemented with 2.5% DQ collagen 
and imaged live. The results in Figure 3.10.1 indicate that the multicellular structures 
formed by the DCIS Rap1Gap shRNA cells exhibit an increase in collagen IV 
degradation (brighter green fluorescence) compared to the lentiviral control.  Collagen 
IV degradation appears to be either contained within the cells (as seen in kd2 line) or 
occurs pericellularly and dispersed farther across the 3D landscape.  This observed 
degradation of collagen IV could be due to the activity of proteases, since they are 
involved in the malignant progression and play a role in aggressive phenotype (Moin, 
Sameni et al. 2012).  More studies are needed to further test this hypothesis. 
To further analyze the effects of lentiviral silencing on proteolytic degradation, 3D 
reconstructions of z stacks (Figure 3.10.2) were made to show depth of collagen IV 
degradation.  More detailed investigation of green fluorescence of the structures (63x 
magnification, collapsed z stacks in Figure 3.10.3) indicates that proteolysis can be 
pericellular or within the cell. Thus, lentiviral silencing of Rap1Gap results in increased 
proteolysis. 
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Figure 3.10.1: Silencing of Rap1Gap leads to increased collagen IV degradation.  
 
Cells were cultured for 8 days in rBM supplemented with DQ collagen.  Structures were 
imaged live to detect presence of cleavage products (green fluorescence). Blue 
represents nuclei.  Images, taken at 20x magnification, were taken at equatorial 
position.  Scale bar, 50 µm. 
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Figure 3.10.2: Silencing of Rap1Gap leads to increased collagen IV degradation. 
 
The panels in this figure are 3D reconstruction of z-stacks of the images in Figure 
3.10.1. The red is dsRed, a reporter protein for the lentiviral transduction. Blue is 
Höechst stain of the nuclei of live cells. Green fluorescence is the result of cleavage of 
DQ collagen IV.  The yellow color observed in kd2 is co-localization of the red reporter 
(dsRed) and green fluorescence as a result of proteolysis.  Images are representative of 
three independent experiments. 
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Figure 3.10.3: Silencing of Rap1Gap leads to increased collagen IV degradation- a 
closer look.  
 
Cells were cultured for 8 days in rBM supplemented with DQ collagen.  Structures were 
imaged live to detect presence of cleavage products (green fluorescence). Blue is 
nuclear stain of live cells. Images, taken at 63x magnification are collapsed Z stacks 
(top panel). The bottom panels are DIC images overlaid with green and blue, and are 
same structures taken at equatorial position. Scale bar, 50 µm.  
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3.11 Rap1Gap re-expression in MCF10.DCIS Rap1Gap shRNA cells reverses 
invasive phenotype 
To further test the role of Rap1Gap in the transition to an invasive phenotype, we 
performed rescue experiments.   Rap1Gap was re-expressed in the DCIS Rap1Gap kd2 
line (which had demonstrated a stronger phenotype in the previous assays: see Figures 
3.6.1, 3.6.3 and 3.9).  GFP was transfected into DCIS Rap1Gap kd2 shRNA cells.  Cells 
were allowed to grow in 2D conditions for 3-5 days before imaging and preparation of 
lysates. Transfected cells were also trypsinized and seeded directly on rBM, to be 
cultured with overlay for 8 days before fixing and staining for F-actin. 
Panel A in Figure 3.11.1 shows successful transient transfection of GFP-
Rap1Gap into the kd2 line by assay of the reporter’s green fluorescence. Panel B 
shows evidence of robust over-expression of GFP-Rap1Gap compared to the GFP- 
control by immunoblotting for Rap1Gap. Figure 3.11.2 displays fluorescent detection of 
F-Actin in DCIS Rap1Gap shRNA cells housing the Rap1Gap over-expression. The 
multicellular invasive outgrowths, characteristic of cells with silenced Rap1Gap 
expression, were blocked, restoring the dense dysplastic structure and F-actin cortical 
rings that are found in MCF10.DCIS.   
 The overlay DIC image in Figure 3.11.3 is a tiled image of 4 contiguous fields 
stitched together to assess the effect of the rescue experiment on other structures in the 
area. This is evidence that the rescue experiment, though transient, has consistent 
effects over time even though not all cells within a structure retain the GFP reporter 
protein. Thus, re-introduction of Rap1Gap DCIS Rap1Gap shRNA cells results in 
reversion of invasive phenotype, characterized by re-appearance of cortical rings. 
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Figure 3.11.1: Rap1Gap Re-expression in MCF10.DCIS shRNA. 
 
A. Images are of MCF10.DCIS cells, previously infected with Rap1Gap shRNA2 (kd2) 
transfected with the GFP-Rap1Gap over expression plasmid. Images shown are at 20x 
magnification of live cells monitored for detection of dsRed (red) and GFP (green). 
Images are representative of two separate transfection experiments that were viewed 3-
5 days post transfection.  B. Parallel lysates from cultures described in panel A were 
prepared and subject to SDS-PAGE and immunoblotting using Rap1Gap and β-tubulin 
antibodies.  β-tubulin serves as a loading control. Images are representative of at least 
three independent experiments. 
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Figure 3.11.2:  Rap1Gap re-expression in MCF10.DCIS Rap1Gap shRNA cells 
reverses invasive phenotype.   
A. Cells were cultured in rBM for 8 days.  The structures were fixed and stained for F-
actin (magenta) and nuclei (blue). Size bar represents 50 µm. These images, taken at 
20x magnification, are representative of 3 independent experiments. B. Expanded 
single image (20x magnification) of DCIS Rap1Gap shRNA kd cells transfected with 
GFP-Rap1Gap from panel A.  Only the magenta signal is shown to emphasize presence 
of actin cortical rings (arrows). 
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Figure 3.11.3: Rap1Gap re-expression in 3D culture. 
 Cells were grown on rBM for 8 days. Structures were fixed and stained for F-actin 
(magenta) and nuclei (blue).  Fluorescent detection of dsRed (red) and GFP (green) 
was also performed. Images are 4 contiguous fields stitched together to cover a wider 
field. Size bar is 150 µm.  
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3.11.1 Re-expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells partially 
restores E-cadherin levels and adherens junctions 
The previous results (Figure 3.11.2) have indicated that Rap1Gap re-expression 
leads to restoration of the dense and compact phenotype and actin cortical rings that 
are characteristic of MCF10.DCIS cells in rBM culture.  We have also shown that 
lentiviral silencing of Rap1Gap leads to marked decrease in E-cadherin and breakdown 
of adherens junctions (Figure 3.7). We therefore wanted to investigate whether E-
cadherin is re-expressed upon re-introduction of GFP-Rap1Gap.  Transfected cells 
were seeded in 3D and allowed to grow for 8 days.  Structures were fixed, processed 
and stained for E-cadherin. As seen in Figure 3.11.4 panel A, and Figure 3.11.5, re-
introduction of Rap1Gap in the kd2 line partially restores adherens junctions.  The 
immunoblot in Figure 3.11.4 panel B shows increase in E-cadherin protein levels 
following re-expression of Rap1Gap toward the level in control MCF10.DCIS cells.  Re-
expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells results in partial 
restoration of E-cadherin levels and adherens junctions. 
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Figure 3.11.4: Re-expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells 
partially restores   E-cadherin levels and adherens junctions.  
 
A. Cells were cultured in 3D for 8 days.  Structures were then fixed and stained for E-
cadherin (magenta) and nuclei (blue). Images taken at 20x magnification.  Scale bar 
represents 50 µm. B. GFP-Rap1Gap transfected cells were seeded in rBM for 8 days. 
Lysates were prepared and subjected to SDS-PAGE and immunoblotting for Rap1Gap 
and β-tubulin (loading control). 
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Figure 3.11.5: Re-expression of Rap1Gap in MCF10.DCIS Rap1Gap shRNA cells 
partially restores E-cadherin levels and localization. 
 
Shown in magenta, fluorescent probe detection of E-cadherin in DCIS Rap1Gap shRNA 
cells transfected with GFP-Rap1Gap that had been cultured in 3D for 8 days.   Image is 
a single and expanded version of the previous image in Figure 3.11.4 (middle image, 
bottom row, A) to emphasize the localization of E-cadherin. Arrows point to localization 
of E-cadherin. 
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3.12 Lentiviral silencing of Rap1Gap in MCF10.DCIS causes an increase in Rap1 
activity 
Given that Rap1Gap is a negative regulator of Rap1, we reasoned that 
knockdown of Rap1Gap would result in an increase in Rap1 activity.  Cells were grown 
in 2D for 5 days or until 70% confluency and serum starved overnight. Rap1 activity 
assays were performed to detect active Rap1. As seen in Figure 3.12, modest Rap1 
activity is observed in the control.  Rap1 activity was increased in both of the DCIS 
Rap1Gap shRNA lines (kd1 and kd2) and MCF10.CA1d.  In addition, re-expression of 
GFP-Rap1Gap caused a reduction in Rap1 activity. Panel B shows densitometry 
analysis of active Rap1.  We show that while silencing of Rap1Gap in MCF10.DCIS 
increases Rap1 activity, re-expression of Rap1Gap reduces Rap1 activity. 
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Figure 3.12: Lentiviral silencing of Rap1Gap in MCF10.DCIS causes an increase in 
Rap1 activity.  
A. Cells were grown until 70% confluency and serum starved overnight. Total Rap1 was 
used to verify even loading of lysate used in the actity assay.  B. Densitometric scans of 
active Rap1 and total Rap1. Ratio of Rap1 GTP vs total Rap1. Error bars represent 
standard deviation. Data taken from two separate experiments. 
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 3.13 Rap1Gap silencing in MCF10.DCIS causes increase in ERK1/2 MAPK 
activation  
Previous immunohistochemical studies show increased MAPK/ ERK1/2 signaling 
in breast cancers compared to normal tissue via IHC (Sivaraman, Wang et al. 1997), 
and that primary tumors of node positive patients have relatively higher ERK1/2 
activation (Mueller, Flury et al. 2000).  Hence, we hypothesized that Rap1Gap silencing 
may result inERK1/2 MAPK activation.  
Cells were grown in rBM for 8 days and lysates were harvested, subjected to 
SDS-PAGE and immunoblotting ERK1/2.  The results in Figure 3.12, panel A, show 
increased phosphorylation of ERK1/2 in MCF10.DCIS cells with silenced Rap1Gap 
expression (lines kd1 and kd2) grown in 3D.  An even more robust increase in ERK1/2 
phosphorylation was observed in MCF10.Ca1D cells. Panel B is box-whisker plot of 
ERK1/2 activation in lysates harvested from 3D conditions. One-way ANOVA statistical 
analysis was performed with a p value = 0.0006. Thus, silencing of Rap1Gap in 
MCF10.DCIS results in increase in ERK1/2 activation. 
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Figure 3.13: Rap1Gap knockdown in MCF10.DCIS causes increase in ERK1/2 
MAPK activation. 
 
A. Lysates were prepared from cells were grown in rBM for 8 days and subjected to 
SDS PAGE and immunoblotting.  The blot was first probed for ppERK1/2 and then 
stripped and reprobed for total ERK1/2. B. Box whisker plot shows densitometry % ratio 
of phosphorylated ERK1/2 vs. Total ERK1/2 from immunoblots from three separate 
experiments.  
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CHAPTER 4: DISCUSSION 
4.1 NGS, qPCR validation, and immunoblotting of Rap1Gap 
This dissertation project aimed to delineate the role of Rap1Gap in the 
progression to invasive breast cancer by using the MCF10 progression series, in the 
context of 3D.  Previous data from NGS studies revealed Rap1Gap was consistently up-
regulated in MCF10.DCIS and two other DCIS lines- SUM 225 (derived from a chest 
wall recurrence) and SUM 102, an extensive primary DCIS with micro-invasion (Kaur, 
Mao et al. 2013), compared to MCF10A cells, a model of non-transformed breast 
epithelium. Further mining of the NGS data revealed significantly enriched common 
frameworks (as referenced in Table 1), with a 336 fold enrichment.  This suggests that 
up-regulation of Rap1Gap is a pivotal part of the DCIS signature. 
Validation of NGS results via qPCR show that Rap1Gap transcripts are low in 
MCF10A and are increased in MCF10.DCIS and SUM 225 cells. However, Rap1Gap 
transcripts are low in SUM 102 cells, which is not in agreement with the initial 
transcriptome analysis. There are several explanations for such a difference. One could 
be that while NGS was performed on RNA of cells grown in 3D, the qPCR analysis was 
performed on RNA from cells grown in 2D.  This is not surprising, as several instances 
of differences in gene and protein expression in 2D and 3D are documented. For 
example, in several epithelial ovarian cancer cell lines, β-catenin and BRCA1 were 
upregulated in 2D vs 3D environment (Lee, Mhawech-Fauceglia et al. 2013). Higher 
expression of cleaved caspase-3 is observed in 3D structures compared to 2D 
monolayer culture (Lee, Mhawech-Fauceglia et al. 2013). Additional examples such as 
differences in drug sensitivity, differentiation, etc. in the breast cancer models are 
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mentioned in section 1.7. A potential technical difference worthy of mention is the 
passage number of SUM 102 cells used in both the mRNA seq and qPCR analysis 
might be different, resulting in the difference in the results. Another technical difference 
is the probes/primers used in the mRNA seq and qPCR analysis, which would target 
different exons of the same gene.  
In lysates prepared from cells grown in 3D, Rap1Gap protein levels are also low.  
This implies post-transcriptional regulation of Rap1Gap.  One possible explanation is 
that in the breast, Rap1Gap might be subject to proteasome degradation (Wang, Zhang 
et al. 2014).  
Immunoblotting results show that MCF0A cells express little Rap1Gap, whereas 
it is increased in MCF10.DCIS. Compared to lysates extracted from cells grown in 2D, 
Rap1Gap levels in MCF10.Neo T cells are significantly higher.  This is interesting, since 
MCF10.Neo T cells are a model of transformed epithelial cells.  MCF10.Neo T cells 
were transformed by transfection with mutated H-Ras (Dawson, Wolman et al. 1996). A 
possible explanation is that increase in Rap1Gap might initially antagonize 
transformation initiated by Ras. This would be consistent with models where Rap1 is an 
antagonist of activated Ras (Tsygankova, Prendergast et al. 2007) and the data that 
decrease and increase of Rap1 Gap levels increases and decreases Rap1 activity 
levels, respectively (Figure 3.12).  Down regulation of Rap1Gap leads to activation of 
ERK1/2/MAPK (Figure 3.13), which may correlate with invasive phenotype 
(Tsygankova, Prendergast et al. 2007).  Rap1Gap levels are reduced in MCF10.CA1D 
cells (Figure 3.1). These findings led us to hypothesize that reduction of Rap1Gap 
would play a role in the progression to invasive breast cancer.  
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Interestingly, rather than overexpression of Rap1Gap, there has been interest in 
loss of Rap1Gap in cancer. For example, studies show that down-regulation of 
Rap1Gap has been linked to invasion and EMT in multiple cancers (Zhang, Chenwei et 
al. 2006, Zhang, Mitra et al. 2006, Zheng, Gao et al. 2009, Tsygankova, Ma et al. 2010, 
Zuo, Gandhi et al. 2010).  There is one published study that mentions mutations of 
unknown significance have been observed in breast cancer (Sjoblom, Jones et al. 
2006). We show that the loss of Rap1Gap may act as a switch in the progression to 
invasive breast cancer. I show that down-regulation of Rap1Gap via lentiviral silencing 
leads to increased Rap1 and ERK1/2 MAPK activation.  Cells acquire an invasive 
phenotype, characterized by extensive cytoskeletal remodeling and enhanced invasion. 
4.2 Rap1Gap is decreased in invasive breast cancer cell lines  
Protein expression of Rap1Gap is increased in DCIS and decreased in invasive 
breast cancer cell lines. Some invasive breast cancer cell lines (i.e., MDA-MB-231, 
BT549, and Hs578t) exhibit a mesenchymal phenotype in 2D and stellate phenotype in 
3D.  We hypothesized that MCF10.DCIS cells, which exhibit an epithelial phenotype 
characterized by wide cellular bodies and some adherens junctions, would acquire a 
fibroblastic phenotype when Rap1Gap is silenced. Cells acquired a spindle shape 
(Figure 3.4), with observed reduction in E-cadherin as a result of lentiviral silencing 
(immunofluorescence images and immunoblot in Figure 3.7). In a 3D environment, 
MCF10.DCIS cells form compact dysplastic structures that model DCIS in vivo. 
Adherens junctions (visualized as the localization of E-cadherin, a major component of 
adherens junctions) and cortical rings (F-actin) are visible in these structures when 
assayed by immunofluorescence.  The MCF10.DCIS cells transduced with Rap1Gap 
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shRNA acquire a starkly contrasting phenotype.  The majority of the structures with the 
Rap1Gap shRNA form long invasive outgrowths, signifying reorganization of F-actin that 
enables cell elongation and directional motility (Thiery and Sleeman 2006, Yilmaz and 
Christofori 2009, Yilmaz and Christofori 2010). Thus, lentiviral silencing of Rap1Gap in 
DCIS leads to at least two phenotypic changes:  reduction of E-cadherin and F-actin re-
organization. 
Such an array of phenotypic changes would be consistent with the characteristics 
of EMT. There are three types of EMT. Type 1 EMT occurs in implantation, 
embryogenesis and organ development; Type II occurs in tissue regeneration and 
organ fibrosis; Type III is reported in cancer (Kalluri and Weinberg 2009). In this 
discussion, the focus is on type III EMT, which is most germane to cancer.  EMT is 
described as a complex, transient and reversible process, characterized by the loss of 
epithelial characteristics (such as cell–cell attachments, adhesion, and apical–basal 
polarity) and the gain of mesenchymal characteristics (such as increased motility, 
invasive properties, and a spindle-like morphology) (De Craene and Berx 2013). Studies 
have suggested that loss of functional E-cadherin contributes to EMT, where epithelial 
cells exhibit loss of cell-cell adhesion, increased motility and invasiveness (Thompson, 
Torri et al. 1994).    Depletion of Rap1Gap in DCIS caused a reduction in E-cadherin 
and dissolution of adherens junctions. 
4.3 Silencing of Rap1Gap in MCF10.DCIS leads to cytoskeletal remodeling 
In addition to alterations in adherens junctions, MCF10.DCIS Rap1Gap shRNA 
cells exhibit invasive outgrowths and distinct cytoskeletal remodeling. Epithelial cells 
possess apico-basal polarity which helps anchor them to the basement membrane; 
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changes from apico-basal polarity to front-rear polarity occur during EMT (Lamouille, Xu 
et al. 2014).  Since the outgrowths appear flattened (as depicted in the 3D 
reconstructions), it is possible that the transition to front-rear polarity is occurring, and 
could be further investigated.  
Vimentin has been widely reported as a marker of EMT (Mendez, Kojima et al. 
2010), and in breast cancer, vimentin is found to be highly expressed in high-grade 
ductal carcinomas (Liu, Zhang et al. 2013). Vimentin cannot be used as an EMT marker 
in this project. MCF10.DCIS cells already abundantly express vimentin. Increase in 
vimentin expression as a result of silencing of Rap1Gap in MCF10.DCIS was not 
confirmed.  In addition to F-actin reorganization (immunofluorescence images, Figure 
3.8.2), we show reorganization of vimentin occurs as a result of Rap1Gap silencing 
(immunofluorescence images, Figure 3.8.3).  Here, we emphasize that in these studies, 
vimentin is re-organized in DCIS Rap1Gap shRNA cells.  In the future, EMT could be 
confirmed by evaluating the emergence of quintessential EMT markers such as N-
cadherin, Twist, Snail or Zeb (Sanchez-Tillo, Liu et al. 2012) via immunoblotting or other 
methods.   
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4.4 Silencing of Rap1Gap leads to enhanced invasion in MCF10.DCIS 
Given the observed cascade of phenotypic changes that have been elicited by 
the silencing of Rap1Gap in MCF10.DCIS, we hypothesized that the 3D structures 
formed by DCIS Rap1Gap shRNA cells may be invasive.  The results from invasion 
assays performed (Figure 3.9, panel A) show a significant increase in invasion when 
Rap1Gap is silenced.  One observation is that there was a very small number of 
invading MCF10.DCIS cells.  This phenomenon is in agreement with previous work, 
which shows evidence of some invasion by MCF10.DCIS, both in vivo and in vitro 
(Miller, Santner et al. 2000, Li, Mullins et al. 2008). The number of DCIS Rap1Gap 
shRNA cells that invaded was significantly higher than the control.  The invasion assay 
was performed in a semi-3D environment, with a coating of 2 mg/ml Cultrex®.  The 
results of the invasion assay indicate that the cells are motile and are able to move 
through the Cultrex® and the pores of the membrane.   
4.5 Silencing of Rap1Gap in MCF10.DCIS leads to increased collagen IV 
degradation 
We have shown that re-organization of F-actin and dissolution of adherens 
junctions is associated with the invasion process of MCF10.DCIS cells when Rap1Gap 
is silenced.  This finding led us to question another interesting aspect of the invasion 
process- remodeling by proteases.  Given the stark phenotypic changes acquired by 
Rap1Gap silencing in MCF10.DCIS cells, and given the observed enhanced invasion 
capability, we hypothesized that increased degradation of type IV collagen would play a 
role in invasion, and that silencing of Rap1Gap in MCF10.DCIS would lead to increased 
proteolysis.  
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In the breast, the basement membrane (BM) is the main ECM that interacts with 
the luminal and myoepithelial cells of the breast duct. It is primarily made up of entactin, 
proteoglycans, laminins and collagen type IV (Oskarsson 2013).   We showed that 
Rap1Gap silencing in MCF10.DCIS cells enhanced intracellular degradation of collagen 
type IV (Figure 3.10.1, Figure 3.10.2 and Figure 3.10.3). Many proteases are involved in 
the remodeling of the ECM. In breast cancer; for example, the participation of cysteine 
cathepsins has been reported (Sameni, Moin et al. 2000) (Curino, Engelholm et al. 
2005). The type of protease involved here is yet to be confirmed and characterized, and 
is a potential focus of future projects.  Some studies have shown that Rap1Gap plays a 
role in metastasis and extravasation via inside-out signaling of the integrins, particularly 
β-1 integrin (Kato, Liao et al. 2012) in melanoma.  This is particularly intriguing because 
independent studies have elegantly reported that β-1 integrin promotes collagen type IV 
degradation in breast and prostate cancers cells, and that reduction of β-1 integrin 
expression and function reduced degradation of dye quenched collagen IV and invasion 
(Sameni, Dosescu et al. 2008). Even though the proteolysis assay was performed over 
a period of 8 days, it complements the results of the invasion assay.  We hypothesize 
that the cells secrete proteases to move through the rBM. 
4.6 Re-expression of Rap1Gap leads to reversal of invasive phenotype 
The cascade of phenotypic changes that silencing of Rap1Gap has elicited in 
MCF10.DCIS has been addressed.  As a control, to confirm whether these changes are 
due to reduction in Rap1Gap, rescue experiments were performed. We transiently re-
introduced GFP-Rap1Gap into the DCIS Rap1Gap shRNA#2 (kd2) cells (Figure 3.11.2).  
Re-introduction of Rap1Gap inhibits the formation of invasive outgrowths.  The 
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structures formed are round and compact, and the F-actin cortical rings are present. 
Additionally, we also show that E-cadherin levels increased and adherens junctions are 
partially restored (immunofluorescence images and immunoblot in Figure 3.11.4).   
4.7 Rap1Gap limits Rap1 and ERK1/2 MAPK activation  
The results in Figure 3.12 show that DCIS cells transduced with 
Rap1GapshRNAs exhibit higher Rap1 activation, and that Rap1 activation is reduced 
following re-expression of Rap1Gap.  There is also a significant increase in ERK1/2 
MAPK activation in the knockdown cells grown in 3D compared to the control (Figure 
3.13). ERK1/2 MAPK signaling is stronger in the shRNA#2 (kd2) compared to Rap1Gap 
shRNA#1 (kd1).  Previous studies from our laboratory have confirmed the presence of 
activated H-Ras in MCF10.DCIS (Li and Mattingly 2008).  This is expected because 
MCF10.DCIS is isogenic to the MCF10.NeoT cell line (see section 1.2 for more 
information), which harbors the constitutively active T24-H-Ras (Dawson, Wolman et al. 
1996).  Since H-Ras is already constitutively active in MCF10.DCIS, the assumption is 
that DCIS Rap1Gap shRNA cells also harbor constitutively active H-Ras. Since ERK1/2 
is further activated in the DCIS Rap1Gap shRNA cells, we conclude that Rap1 and 
Rap1Gap might participate in downstream signaling, between H-Ras and ERK1/2. 
Rap1Gap and Rap1 may regulate ERK1/2 by antagonizing signals relayed by H-Ras. 
4.8 Alternative mechanisms 
Other mechanisms have been proposed to delineate the role of Rap1Gap in 
cancer progression. For example, studies show that overexpression of Rap1Gap in 
pancreatic cancer cells lines (Zhang, Chenwei et al. 2006) resulted in inhibition of FAK 
activation and cell spreading without changes in ERK1/2/MAPK phosphorylation. On the 
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contrary, studies in melanoma show that Rap1Gap over-expression leads to reduced 
ERK/MAPK phosphorylation (Zheng, Gao et al. 2009). Previous studies in different 
cancers have reported that blockage or RNAi of ERK1/2 inhibits migration and invasion 
in prostate and human osteocarcinoma cells respectively. (Si, Peng et al. 2012, Li, Li et 
al. 2013). In the context of ductal breast cancer, ERK1/2 also mediates invasive breast 
ductal cancer cell migration and invasion (Ma, Lan et al. 2012).   Our findings are in 
agreement with these reports. Other studies have also shown that Rap1 could exert its 
effects through Src and FAK. For example, depletion of Rap1Gap in colon cancer cells 
induces increase in Src and FAK activation (Tsygankova, Ma et al. 2010). In addition to 
the regulation of E-cadherin, inside-out signaling via the integrins, which link the ECM to 
the actin skeleton at focal adhesion sites, is also regulated by Rap1, via Src activity 
(Hynes 2002). We investigated Src phosphorylation profiles in MCF10.DCIS vs 
MCF10.DCIS shRNA cells, which are discussed in Chapter 5. 
 Rap1 may regulate recycling, avidity and affinity of the integrins that are 
associated with the actin cytoskeleton, including α3β1, α4β1, αLβ2, αIIbβ3 (Bos, de Bruyn 
et al. 2003, Caron 2003, Dustin, Bivona et al. 2004, Bos 2005). Studies in pancreatic 
cancer cells support the role of Rap1Gap in the regulation of integrin activation (Zhang, 
Chenwei et al. 2006). Thus, Rap1Gap plays a pivotal role in integrating cell-cell 
adhesion and ECM (extracellular matrix) attachment in both normal and malignant 
conditions.  
4.9 Other GAPs, Rap1Gap2 
Previous studies have shown that various GAPs, related to Rap1Gap, are 
implicated in proliferative disorders that are similar to cancer. For example, mice 
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deficient in Spa-1 develop a spectrum of myeloid disorders that resemble chronic 
myeloid leukemia (Ishida, Kometani et al. 2003). Another member of Rap1Gap family, 
E6TP1 (Singh, Gao et al. 2003), contributes to cervical cancer and other cancers 
associated with chronic human papilloma virus infection. It is targeted for ubiquitin 
mediated degradation by viral E67 oncoprotein.  
The biological functions of Rap1Gap2 are not widely studied. Studies on 
Rap1Gap2 have involved elucidating its potential role in platelet aggregation 
(Hoffmeister, Riha et al. 2008, Neumuller, Hoffmeister et al. 2009), axonal outgrowths in 
olfactory sensory neurons (Sadrian, Cheng et al. 2012) and sex specific association of 
asthma incidence in Latina females (Myers, Scott et al. 2014).  In the context of cancer, 
IHC analysis shows Rap1Gap2 has been shown to be moderately or highly expressed 
in thyroid cancer, lobular and ductal carcinomas. 
(http://www.proteinatlas.org/ENSG00000132359-RAP1GAP2/cancer).  
In summary, lentiviral shRNA silencing of Rap1Gap in MCF10.DCIS induced 
increase in cell proliferation, Rap1 and ERK1/2/MAPK activity, appearance of 
outgrowths, extensive cytoskeletal reorganization, increase in proteolytic degradation of 
collagen IV and acquisition of invasiveness.  Re-expression of Rap1Gap in 
MCF10.DCIS-Rap1GapshRNA cells reduced Rap1 activity and suppressed the 
development of invasive outgrowths in 3D structures. Thus, reduction of Rap1Gap in 
DCIS may act as a switch to progression to an aggressive phenotype via deregulated 
Rap1 and ERK1/2/MAPK activation. 
  This is the first mechanistic study of Rap1Gap in breast cancer. We have 
developed a model in which over-expression of Rap1Gap may be linked to pre-
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malignant progression of breast cancer, whereas subsequent reduction in Rap1Gap 
may act as a switch to invasive phenotype.  As depicted in the model in Figure 4, 
Rap1Gap protein levels are highest at DCIS stage. Upregulation of Rap1Gap protein in 
DCIS correlates with E-cadherin delocalization and leads to decreased Rap1 and MAPK 
activation. Down-regulation of Rap1Gap is proposed to be a molecular switch for 
progression to invasive ductal carcinoma.  Loss of Rap1Gap leads to increase in Rap1 
and ERK1/2 /MAPK activation, weakening of cell-cell junctions, cytoskeletal remodeling 
and invasion.  Subsequently, increased cell motility and invasion will ensue. Re-
expression of Rap1Gap causes reversal of the invasive phenotype, which includes 
reappearance of cortical rings, partial restoration of E-cadherin expression and 
localization consistent with adherens junctions. 
Despite the improvement in detecting DCIS, our understanding of the molecular 
evolution in DCIS is scarce. The results obtained from this study may lead to diagnostic 
tools that can be used to discern the difference between DCIS lesions that remain 
indolent and those that are likely to progress.  
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Figure 4: Model. Rap1Gap protein levels culminate at DCIS stage. The over 
expression of Rap1Gap protein in DCIS leads to E-cadherin delocalization, decrease in 
Rap1 and ERK1/2 activity. Downregulation of Rap1Gap is a molecular switch for 
progression to invasive ductal carcinoma, occurring through dramatic increase in Rap1 
and ERK1/2 activation. Invasive phenotype, characterized by appearance of 
multicellular outgrowths, weakening of adherens junctions, extensive cytoskeletal 
remodeling ensues.  Re-expression of Rap1Gap inhibits manifestation of the invasive 
phenotype via decrease in Rap1 activity and inhibition of appearance of invasive 
outgrowths.  
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CHAPTER 5: OTHER DIRECTIONS 
5.1 The original hypothesis- Rap1Gap and Src 
The original hypothesis of this dissertation was that loss of Rap1Gap, leading to 
activation of Rap1 and Src kinase, drives the transformation of DCIS to invasive 
carcinoma via deregulation of epithelial junctions and cell matrix attachments. 
5.1.1 Src Kinase 
  Src is a non-receptor protein tyrosine kinase that transduces signals that are 
involved in the control of a variety of cellular processes such as proliferation, 
differentiation, motility, and adhesion (Gelman 2011). Src was initially identified by 
Peyton Rous in 1911 as the transforming agent in chicken sarcomas. Since then, a 
whole family of Src kinases has been discovered.  Src family kinases play a critical role 
in cell adhesion, invasion, proliferation, survival, and angiogenesis during tumor 
development (Lutz, Esser et al. 1998).  Overexpression or high activation of Src kinase 
occurs frequently in tumor tissues and they are central mediators in multiple signaling 
pathways that are important in oncogenesis (Lutz, Esser et al. 1998). Activation of Src 
occurs as a result of disruption of the negative regulatory processes that normally 
suppress Src activity (Bjorge, Jakymiw et al. 2000). In epithelial cells, activation of Rap1 
is associated with increased Src kinase activity (Retta, Balzac et al. 2006). Disruption of 
adherens junction and enhanced cell matrix adhesion are associated with increased or 
over activated Src (Bailey, Kelly et al. 2009).  In epithelial cells, as depicted in Figure 
5.1, strong activation of Rap1 by E-cadherin is associated with and controlled by Src.  
In addition to the regulation of E-cadherin, inside-out signaling via the integrins, which 
link the ECM to the actin skeleton at focal adhesion sites, is also regulated by Rap1, via 
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Src kinase activity (Hynes 2002). Specifically, Rap1 may regulate recycling, avidity and 
affinity of the integrins that are associated with the actin cytoskeleton, including α3β1, 
α4β1, αLβ2, αIIbβ3 (Bos, de Bruyn et al. 2003, Caron 2003, Dustin, Bivona et al. 2004, 
Bos 2005). Studies in pancreatic cancer cells support the role of Rap1Gap in the 
regulation of integrin activation (Zhang, Chenwei et al. 2006). Additionally, studies in 
colon cancer cells highlight the downstream of action of Rap1Gap to Src; in Rap1Gap 
depleted cells, Src activity was increased (Tsygankova, Ma et al. 2010). Thus, these 
studies lead me to hypothesize that Rap1Gap may play a pivotal role in integrating cell-
cell adhesion and ECM attachment in both normal and malignant conditions via Src, in 
the realm of breast cancer. 
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Rationale:  Rap1Gap and Src together play a role in the maintenance of adherens 
junctions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Pictorial depiction of Rap1 and Src and their role in the maintenance 
of adherens junctions in epithelial cells.  
 
Rap1 is diffusely distributed into the cytoplasm.   Activation of Rap1, associated with Src 
(circled in red) activation leads to weakening of cell-cell junctions.  E-cadherin, β-catenin 
and p120 catenin localization are altered, leading to weakening of the adherens 
junctions.  Image taken with permission from Balzac, F., Avolio, M., Degani,S., 
Kaverina, I. Torti,M,.  Silengo, L, J.  Small, V., Retta, S. F. J Cell Sci 2005;118:4765-
4783.  
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5.1.2 Src activation profiles are dramatically different in 2D vs. 3D 
microenvironments 
Based on previous reports, we hypothesized that Rap1Gap down regulation 
leads to Src activation and acts as an impetus for the acquisition of invasive phenotype 
in DCIS.  On the contrary, the results show the opposite of this original hypothesis.  
Figure 5.2 shows immunoblots of Src phosphorylation profiles in the MCF10 series – in 
2D vs. 3D conditions. Phosphorylation of Src at tyrosine-416 has been linked to its 
activation (Harvey, Hehir et al. 1989).  Here, in panel 2A, in lysates prepared in 2D 
conditions, we show that Src is phosphorylated in MCF10A and MCF10.Ca1d cells.  
However, there is little apparent difference in Src phosphorylation in one of the DCIS 
Rap1Gap shRNA lines (kd1) compared to the MCF10.DCIS control.  
Figure 5.2 panel B shows a dramatic change in Src phosphorylation in the 
MCF10 series in lysates harvested from 3D cultures.  MCF10A cells exhibit robust 
phosphorylated Src.    DCIS Rap1Gap shRNA #1 (kd1) and DCIS Rap1Gap shRNA #2 
(kd2) have lower Src phosphorylation profiles, with a slightly higher Src phosphorylation 
in kd1. There are other notable instances of similar dose-dependent responses between 
the kd1 and kd2 in other experiments in this dissertation. In lysates grown in 3D, Src 
phosphorylation is higher in the lentiviral control compared to the parental line. This 
might be due to an artifact of the viral transduction. This does not change the conclusion 
that Src phosphorylation is dramatically reduced in the DCIS cells with the Rap1Gap 
shRNA. The differences in Src activation in 3D vs. 2D environments is striking.  The 
data here reveal down-regulation of Src phosphorylation by Rap1Gap silencing that is 
not evident in a 2D microenvironment.  
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The conclusion drawn from this experiment is that in the MCF10 progression 
series, Rap1Gap might not work through Src in the process of invasion. There is one 
other study done on human alveolar basal epithelial cells (A549 cells) that shows that 
cell spreading and focal adhesion formation can be directed by Rap1 without Src 
involvement (Ross, Spanjaard et al. 2012). 
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A 
 
 
 
B 
 
 
Figure 5.2: MCF10 series cells grown in 2D and 3D conditions reveal stark 
differences in Src activation.  
 
A. Lysates prepared from cells grown in 2D conditions and subjected to SDS PAGE  
and immunoblotting and detection of perch and total Src. GAPDH was used as a 
loading control. B. Cells were allowed to grow in 3D for 8 days and  lysates were 
prepared and subjected to SDS-PAGE. Immunoblot shows detection of pSrc and total 
Src.  Results are representative of three experiments. 
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5.2 Rap1Gap over-expression in SUM 102 cells 
A significant portion of this work revolves around the employment of 
MCF10.DCIS as model to demonstrate the potential role of Rap1Gap in the progression 
of DCIS. We propounded the idea that depletion of Rap1Gap unleashes the acquisition 
of invasive phenotype.  As mentioned earlier in this dissertation, SUM 102 cells are 
characterized as a DCIS with micro-invasion (Barnabas and Cohen 2013). We have 
shown that this basal cell line expresses reduced levels of Rap1Gap (Figure 3.2). Since 
SUM 102 is a DCIS with micro-invasion, we reasoned that over-expression of Rap1Gap 
would induce morphological and underlying molecular changes that are reminiscent of a 
non-invasive DCIS. 
The immunoblot results in Figure 5.3 show that robust Rap1Gap over-expression 
was achieved.  When the cells were monitored post transfection, we observed that the 
many of the cells were not viable, and therefore more sensitive to transfection with 
plasmid.  This might be explained by the effects of over-expression of Rap1Gap on cell 
viability and proliferation.  Due to the sensitivity of these cells to transfection with 
Rap1Gap, it was not practical to further pursue this part of the project. Further 
investigation of the effect of Rap1Gap over-expression on the viability and potential 
inhibition of SUM 102 cell proliferation would be needed. 
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Figure 5.3: Rap1Gap overexpression in SUM 102 cells.  
 
A.  SUM 102 cells were transfected with GFP Rap1Gap as indicated. DIC images of live 
cells were taken 3-4 days post transfection.  The overlaid green fluorescence shows 
GFP reporter of Rap1Gap over-expression. B. After 5-7 days of transfection, lysates 
were prepared and subject to SDS-PAGE. Immunoblot of Rap1Gap over-expression in 
SUM 102 cells. β-tubulin was used as a loading control. 
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5.3 Rap1Gap over-expression in MCF10A cells 
As described earlier, both at the mRNA and protein levels, Rap1Gap was 
observed to be upregulated in MCF10.DCIS compared to MCF10A cells, a model of 
non-transformed mammary gland epithelium.  We have presented data that support the 
hypothesis that Rap1Gap, when lost, manifests in an invasive phenotype in DCIS.  
Additionally, as noted in other studies, Rap1Gap may act as a tumor suppressor 
(Zhang, Chenwei et al. 2006). Therefore, we aimed to address the question whether the 
observed over-expression of Rap1Gap in DCIS drives the development to DCIS from a 
non-transformed state or if it is a tumor suppressive response to the development of 
DCIS.  Hence, we decided to transiently overexpress Rap1Gap in MCF10A cells, a 
model of normal breast epithelium. 
 The DIC images in Figure 5.4, panel A show that the MCF10A cells transfected 
with GFP control form structures that resemble non-transformed MCF10A cells. Panel B 
shows an immunoblot of efficient over-expression of Rap1Gap in MCF10A cells.   The 
MCF10A cells transfected with GFP-Rap1Gap from structures that appear essentially 
similar to the control MCF10A though slightly bigger.  They are not reminiscent of 
MCF10.DCIS, which are dense and dysplastic. Unlike MCF10A cells, which form hollow 
lumens when grown in rBM, dysplastic structures are characterized by disorganized 
nuclei and inability to form lumens. The interpretation of these images does not allow us 
to conclude that Rap1Gap overexpression drives the progression towards DCIS.  It is 
possible that the up-regulation of Rap1Gap is more likely a response to the 
development of DCIS; i.e. a potential suppressor of progression to DCIS stage. 
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Figure 5.4: Rap1Gap overexpression in MCF10A cells. 
 
 A. Five days after transfection, single cell suspensions were seeded in 3D and allowed 
to grow for 8 days. Contiguous DIC 2x2 stitched images were taken to assay a wider 
field of cells.   Scale bar, 50 µm. B.  Cells were transfected with GFP Rap1Gap and 
lysates were made and subjected to SDS-PAGE and immunoblotting. GAPDH was 
used a loading control. 
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The purpose of this study is to determine the role of Rap1Gap in the progression 
of DCIS (ductal carcinoma in situ) to IDC (invasive ductal cancer). We employed an in-
vitro three-dimensional (3D) overlay model that provides a physiologically relevant 
microenvironment to study mechanisms of malignant progression. Previous studies 
from this laboratory aimed to determine specific gene expression changes common to 
three models of DCIS- MCF10.DCIS, SUM 102 and SUM 225 in comparison to 
MCF10A cells, a model of non-transformed human mammary epithelium.  The 
expression of 295 genes was found to be significantly altered, with 63 being increased 
in expression in all three DCIS cell lines.  
The mRNA-Seq results were further mined by Genomatix analysis to gain an 
insight into common frameworks in promoter regions of these 63 up-regulated genes.  
244 promoter loci were found to be associated with these 63 up-regulated genes.  
Enrichment analysis showed that the common framework RXRF-ZF02-ZF02-PLAG-
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HDBP is highly enriched [336-fold], being present in the promoters of RAP1GAP, 
SPRY4 and PDGFB genes. 
Rap1Gap is a GTPase-activating protein (i.e., an inactivator) for the small 
GTPase, Rap1.  It is known to be involved in regulation of cell adhesion and has been 
previously studied in pancreatic and thyroid cancers, where a decrease in its expression 
has been associated with malignant progression.  Immunoblotting results show that in 
cells grown in 3D, Rap1Gap levels in MCF10.CA1d cells are reduced compared to 
those in MCF10.DCIS cells. Lentiviral shRNA silencing of Rap1Gap in DCIS induced an 
increase in Rap1 and MAPK activity, as determined by Rap1 activity assay and 
immunblotting for phosphorylated ERK1/2. Confocal immunofluorescence (staining of F-
actin) of 3D structures and invasion assays reveal appearance of multicellular 
outgrowths, extensive cytoskeletal organization and increase in invasion. 
Concomitantly, increase in collagen IV degradation was observed. Lentiviral silencing of 
Rap1Gap also resulted in an increase in proliferation. Re-expression of Rap1Gap in 
DCIS-Rap1GapshRNA cells reduced Rap1 activity and suppressed the development of 
invasive outgrowths in 3D structures. Additionally, adherens junctions and E-cadherin 
levels were partially restored. Thus, we conclude that reduction of Rap1Gap in DCIS 
acts as a switch to progression to an invasive phenotype via deregulated Rap1 and 
MAPK activation. 
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